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ABSTRACT 
 
In drug discovery, it is important to use high throughput screening (HTS) 
technologies to rapidly identify active compounds for biological targets (usually enzymes) 
from large chemical libraries. The state of art strategy for HTS is coupling multiwell-
plates (MWPs) to optical readers. Higher throughput, less reagent use and minimal 
labeling are always pursued in HTS. Mass spectrometry (MS) is a powerful label-free 
analyzer due to its high speed and sensitivity. Segmented flow (droplets) can reliably 
manipulate nanoliter samples and miniaturize reactions with high precision and 
automation. Novel high throughput screening systems have been developed by 
interfacing oil-segmented droplets to electrospray ionization (ESI)-MS.  
To miniaturize a screening, we designed an all-droplet system for conducting 
assays inside nanoliter droplets. A microfabricated reagent addition device was used for 
injecting multiple reagents into the droplet array of test compounds to initiate enzymatic 
reactions. The reaction droplets were directly analyzed by ESI-MS. This all-droplet 
system was demonstrated by a cathepsin B inhibitor screening with high reliability (Z-
factor = 0.8), high analysis rate (0.8 Hz) and straightforward interpretation. Reagents 
 xxi 
 
consumption was at picomoles to femtomole level, which is 1000-fold less than the 
traditional MWP-based assays.  
Integrating droplet-ESI-MS with existing MWPs screening workflow can extend 
the application of both systems. With this concept, we developed a „MS plate reader‟ 
(MSPR). It can reformat 3072 samples from eight 384-well plates into oil-segmented 
droplets in 13 min (4.5 Hz), and then analyze them in 30 min (up to 2 Hz). Using MSPR, 
a label-free screen for cathepsin B inhibitors against 1280 chemicals was completed in 45 
min (triplicate assay, 1.6 Hz). 11 novel inhibitors were identified and validated.  
We also developed MS assays for two health beneficial enzymes: SIRT1 and 
SIRT6. Both assays are applicable to large-scale screenings using MSPR. An 80-
compound pilot screening for SIRT1 modulators identified 4 strong inhibitors (> 50% 
inhibition), all of which were confirmed by dose-dependent experiments. A 25-compound 
test screening of SIRT6 modulators demonstrated the reliability of this assay by 
identifying the known activator (> 200% activation). It also showed that the single assay 
is as robust (Z-factor=0.6) as the replicated assay. 
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CHAPTER 1 
INTRODUCTION 
 
High Throughput Screening 
High throughput screening (HTS) has been widely used in drug discovery and 
many related fields of biology and chemistry. To identify biologically active molecules, 
high throughput assays rapidly measure the activity of a large quantity of test compounds 
against certain biological targets. The increasing size of chemical libraries provided by 
combinatorial synthesis, the expanding pool of the targets resulted from our knowledge in 
life science, and the growing demand on rapid determination of physiochemical and 
pharmacological properties of screening hits urge more efficient assay techniques to be 
developed. Common strategies for HTS involve automation, parallelization and 
miniaturization. Many fully automated HTS liquid handling instruments are available on 
the market. For example, the Multidrop Combi (Thermo) can dispense microliter level 
reagents into 384-well plates within 10 s by using 8 parallel reagent transportation tubes; 
the Caliper pin tool and Biomek workstation can transfer all test compounds from a 384-
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well-format library into assay plates in less than 30 s; the Mosquito HTS utilizes tiny 
disposable pins to reliably manipulate down to 10 nL liquid. Generally, high throughput 
is defined as testing 10,000 to 100,000 chemicals per day.
1,2
 In current days, HTS 
technologies are not only used in drug discovery. Searching for catalysts for chemical 
reactions, initiators for polymerization reactions, and mutant proteins for protein 
engineering can all be benefitted from HTS technologies. 
In drug discovery, the most important biomolecule targets include enzymes, G 
protein coupled receptors (GPCRs), nuclear hormone receptors and ion channels. 
Enzymes play significant roles in metabolic processes in life. Over or under-expression, 
and malfunctioning of enzymes often lead to diseases. Molecules that influence the 
activity of enzymes are frequently of interest as drug candidates or chemical biology 
tools. Nearly half of small molecule drugs on the market are enzyme inhibitors.
1,3
 With 
our growing knowledge in life sciences, even more enzymes have been identified as 
potential therapeutic targets.
1
 Thanks to the rapid development in combinatorial 
chemistry, we are supplied with increasingly large-size chemical libraries.
4
 Creating 
novel HTS techniques to screen for enzyme modulators from those libraries is in demand. 
The biochemical assays for finding enzyme modulators are typically performed in 384- 
and 1536-well plates, in which the responses are measured by optical plate readers.
5
  
Fluorescence detection systems are among the most popular readout methods for 
HTS. They are fast, robust, sensitive, and compatible with homogeneous and small 
volume assays.
2
 Despite their many advantages, fluorescence detectors are limited by the 
reliance on incorporating labels or coupling reactions.
6
 Extra effort and expense are 
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typically invested in an assay for generating fluorescent signals; however the success is 
not always guaranteed. Also, false positive signals which are caused by, for example, test 
compounds affecting the label instead of the target reactions and false negative signals 
which are caused by, for example, the label affecting the target reaction, are not rare and 
would cost more money and time in the screening. 
Because of the aforementioned reasons, label-free analysis has gained increasing 
attention in HTS. There are several advantages for screening without optical labels: 1) 
those methods require minimized manipulation on the chemistry being studies; 2) they 
usually do not have artifacts such as auto-fluorescence of certain test compounds; 3) they 
allow studying the primary cells instead of genetically modified ones; 4) and the assays 
are less difficult to develop.
6
 Several label-free screening approaches have been 
established, such as impedance, surface plasmon resonance (SPR), waveguides, photonic 
biosensor, and mass spectrometry.
6,7
  
 
Mass Spectrometry for High Throughput Screening 
Mass spectrometry (MS) is a powerful label-free analyzer. The analysis is entirely 
based on the mass-to-charge ratio of the molecules of interest, and thus avoids the 
interference from artificial labels. MS has been revolutionized in the last two decades 
since the invention of electrospray ionization (ESI) (Figure 1-1) and matrix assisted laser 
desorption ionization (MALDI). Both methods are soft ionization methods, which 
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preserve the integrity of thermo-labile molecules. And due to their wide applicability in 
ionizing a variety of compounds, they have become dominant in MS. 
With the improvement in the sensitivity, selectivity and speed of mass analyzers 
in recent years, both ESI-MS and MALDI-MS have been explored for HTS applications. 
For example, inhibitors of 3 enzymes were screened using MALDI-MS for less than 10 
s/sample;
8
 the commercial FlashQuant
TM
 workstation (MDS Sciex) combining a patented 
MALDI source with a triple quadrupole MS can analyze 96 samples in 5 min (~3 
s/sample); Rapidfire
®
 (Agilent Technologies) which couples automated solid phase 
extraction (SPE) to ESI-MS/MS can analyze complex samples as fast as 6-10 s/sample. 
 
Figure 1-1. Scheme of electrospray ionization.
9
 Reproduced with permission from ACS 
Publications. 
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Further improving the throughput of ESI-MS-based HTS is limited by the slow 
sample introduction approaches. Because of the ion suppression effect on the target 
analytes from non-volatile salts, matrix, surfactants, and co-existing molecules, sample 
preparation is often mandatory prior to the analysis. Also, if too many compounds are 
present in the sample, the dynamic range of MS will be limited because of the saturation 
of both ESI process and the detector. In that case, high performance liquid 
chromatography (HPLC) is required to disperse the molecules. Sample cleanup and 
chromatography improve MS performance, but they decrease the overall throughput. 
To understand ion suppression, one should first understand the basics of ESI. 
Researchers have strived to unveil the true mechanism of ESI for many years. So far, 
three models: ion evaporation model (IEM), charge residue model (CRM) and chain 
ejection model (CEM) best explain how gas-phase ions are formed.
9
 The ESI process is 
generally agreed to be: 1) a high voltage is applied onto the analyte solution inside a 
metal capillary (ESI needle). The solution at the tip of the needle is distorted into a 
Taylor cone. When the repulsion among charges overcomes the surface tension, a jet of 
liquid is emitted, containing many micrometer level droplets.
10
 2) Rapid solvent 
evaporation increases the charge density on shrinking droplets. When Rayleigh limit is 
reached, smaller offspring droplets are formed by fission. After cycles of solvent 
evaporation and fission, nanometer level, highly charged droplets are produced (Figure 
1-1). 3) Gas-phase ions are formed following the aforementioned three mechanisms.  
Low molecular weight molecules are often considered released to gas phase via 
IEM: The electric field on the nanometer droplet is sufficiently high to eject small 
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solvated ions from the surface. The solvation shell will be lost by collisions with 
background gas and finally the ion enters gas phase. Large globular species are 
transferred to gas phase by CRM: The highly charged nanometer droplet containing one 
analyte keeps evaporating until all solvent shells dry. Polymers and unfolded proteins 
undergo ESI by CEM: The hydrophobic chain migrates to the surface of the nanometer 
droplet. When one terminus is expelled into gas phase (like IEM), the rest of the chain is 
sequentially ejected out of the droplet carrying charges on it.
9
 
Based on the ESI mechanisms, solvent evaporation, droplet shrinkage and 
analytes acquiring charges from the droplet surface are key factors affecting ESI 
efficiency. Ion suppression is caused by: 1) matrix components or any other compounds 
competing with target analytes for the access to the droplet surface; 2) interference 
competing with the analytes for surface charges; 3) interference co-precipitating the 
analytes; 4) high concentration non-volatile components increasing  the viscosity and 
surface tension of the sample solution, which reduces the efficiency of desolvation; 5) 
salts forming adducts with the analyte, as a result spreading out the charge state, as well 
as the intensity.
11-13
 Ion suppression increases the limit of detection of the target analyte, 
jeopardizes quantification, and compromises the reproducibility. To resolve this issue, 
sample cleanup, extended sample separation, introducing internal standard, and dilution 
are the main strategies. 
Chromatography hyphenated to MS has become the standard scheme for MS 
analysis as they alleviate ion suppression from matrix and other sample components. The 
potential of chromatography-MS-based HTS has been explored for many years.
14,15
 
 7 
 
Multiplex-liquid chromatography (LC)-MS system arranges several LC columns in 
parallel to improve the throughput
16
. Multiplexed affinity selection assesses protein-
ligand interaction by coupling parallel size exclusion chromatography (SEC) to ESI-
MS.
17,18
 Rapidfire
®
 system (SPE-ESI-MS/MS) analyzes each sample in ~8 s, and a 
multiplex assay has been shown to increase the throughput by 4 folds.
19
 Parallel SPE has 
also been coupled to MS analysis, the throughput of which can be as high as 6 s/sample 
(0.18 Hz).
16,20
  (Figure 1-2 A-C) 
However, the long duty cycle of separation does not match the high scan speed of 
MS. If ion suppression is not severe and sufficient resolution can be achieved by the MS, 
chromatography or sample preparation can be bypassed. Some researchers have 
attempted to bypass the chromatography or sample preparation by using flow injection 
analysis (FIA). In FIA, a series of sample plugs are sequentially injected into a stream of 
aqueous buffer which flows into ESI-MS for continuous analysis. This approach has been 
successfully applied to monitor active ingredients in tablets
21
 and metabolites in cell 
extract.
22
 Utilizing an 8-probe liquid handling system, samples in a 96-well plate can be 
analyzed in 5 min (~3s/sample).
23
 (Figure 1-2 D) 
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B) 
 
 
 
 
 
 
 
 
 
 
 
 
C) 
 
 
 
 
 
 
 
 
D) 
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Figure 1-2. A) Instrument setup of a 4-way parallel LC-MS/MS for high throughput 
analysis.
24
 B) Affinity-based MS binding screening (e.g., SpeedScreen). Ligands, target 
protein, and tracer/target ligand in a 96-well plate (1) are aspirated (2) and subsequently 
dispensed onto a 96-well filtration plate (3). After washing of the filtration plate (4) to 
remove nonbinders, methanol is added (5) to allow disruption and elution of binders (6) 
to another 96-well plate (7) for measurement by LC-MS (8). Quantification of the 
tracer/target ligand by triple-quadrupole MS allows determination of the percentage of 
tracer/target ligand displacement by unknown ligand binders
25
. C) On-line solid phase 
extraction using Rapidfire
® 
(chem.agilent.com): the in-line automated cartridge switching 
can switch up to 12 reusable SPE cartridges (> 2000 injections/cartridge). The system can 
automate 63 plate handling and 60 hours unattended operation with 20000+ injections. D) 
High-throughput flow injection mass spectrometry system. System configuration includes 
the following: HP 1100 series HPLC system, Gilson 215 multiprobe liquid-handling 
system modified to include a Valco Cheminert model C5 eight-position column selection 
valve, and a Micromass LCT electrospray ionization time-of-flight mass spectrometer.
23
 
Reproduced with permission from the publishers. 
 
Although FIA is promising in improving the MS analysis rate, it is limited by the 
nature of single phase continuous flow. Taylor dispersion is a phenomenon associated 
with laminar flow, because of which cross-contamination and band broadening are 
expected. Sample adsorption is also likely to happen because samples are in direct 
contact with the sample channel.
26
 Those issues can be addressed by segmented flow 
system. 
 
Segmented Flow for High Throughput Screening 
Segmented flow is a subcategory of droplet microfluidics. It is a flow system that 
compartmentalizes reagents in nanoliter to picoliter small droplets by the 2
nd
 immiscible 
continuous phases, such as air and oil (Figure 1-3).
27
 The use of perfluorinated oil has 
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gained increasing popularity because it is much less compressible than air. Also, most 
compounds are unlikely to partition into the fluorocarbons.
28
 Protected by the immiscible 
carrier fluid, cross-contamination and adsorption-caused sample loss can be largely 
reduced. Compared with continuous flow, the size of each droplet is significantly lower. 
This feature is especially valuable for HTS as the bottleneck of a screening is often the 
reagent procurement.
29
 Table 1-1 shows the comparison of time and costs for a screening 
using traditional methods and droplet microfluidics.
30
 The advances of microfluidic 
technology allow rapid and flexible control over the droplets. Droplet split,
31
 reagent 
addition,
32
 series dilution,
33
 and sorting
30
 have been realized (Figure 1-4). 
 
Figure 1-3. Segmented flow (droplets) and a modular approach of droplet-based 
screening system.
27
 1) Droplets are pinched off by injecting oil from both sides of a cross 
fitting into the sample stream; 2) droplet library is stored on a spool; 3) the reagent is 
injected into individual droplet through a T-junction to initiate reactions; 4) Fiber optic 
detectors monitor the components of droplets in-line. Reproduced with permission from 
RSC Publishing. 
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Table 1-1. Comparison between traditional HTS and droplet-microfluidic HTS.
30
 
Reproduced with permission from National Academy of Sciences.  
 Robot Microfluidic drops 
Total reactions 5 × 10
7
 5 × 10
7
 
Reaction volume 100 L 6 pL 
Total volume 5000 L 150 L 
Reaction/day 73000 1 × 10
8
 
Total time 2 years 7 h 
Number of plates/devices 260000 2 
Cost of plates/devices $520000 $1 
Cost of tips $10 million $0.3 
Amortized cost of instruments $280000 $1.7 
Substrate $4.75 million $0.25 
Total cost $15.81 million $2.5 
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Figure 1-4. A) Droplet splitting to different ratios by constructing outlet channels with 
different inner diameters;
31
 B) Scheme of reagent addition into droplets;
32
 C) Serial 
dilution using microfluidic dilutor: a buffer droplet approaches (0 ms), contacts the 
A) 
 
 
 
 
 
 
 
 
B) 
 
 
 
 
 
 
C) 
 
 
 
 
 
 
 
 
 
 
 
 
D) 
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mother droplet (10 ms), coalesces and activates the soft valve (20 ms), and finally 
generates an output droplet (35 ms). After a series of buffer droplets passing by, the 
output droplets contain gradually decreased concentration of the sample in the mother 
droplet;
33
 D) Droplet sorting: the drops flow as a solid plug to a junction where oil is 
added to separate the drops. The light drops contain 1 mM fluorescein, and the dark 
contain 1% bromophenol blue. Fluorescence levels are detected as the drops pass a laser 
focused on the channel at the gap between two electrodes. When sorting is on, the light 
drops, which are brighter than the threshold level, are sorted by dielectrophoresis into the 
bottom channel.
30
 Reproduced with permission from publishers. 
 
In recent years, sophisticated droplet microfluidic devices have been built. A 
variety of high throughput assays were tried with them. For example, new mutant 
proteins were screened at kilohertz from directed evolution,
30
 deacetylation reaction 
conditions were optimized with only 20 g reagent consumption,34 a screening for 
photosensitizer activity were carried out with multi-parameter detection,
35
 protein 
crystallization conditions were screened with nanoliter level protein solution use,
36
 high 
throughput dose dependent experiment was performed based on confining concentration 
gradient into droplets, arranged in a serial fashion within a channel.
37
  
Interfacing segmented flow with ESI-MS has been explored for several years. 
Some groups extract the aqueous sample out of droplet system before analysis.
38,39
 Our 
group is pursuing a similar path but we instead directly infuse droplets into a ESI 
source.
40
 An inhibitor screening for acetylcholinesterase (AchE) was performed in 
droplet fashion.
41
 In the study, reaction mixtures were deposited into a 96-well plate and 
then covered by a thin layer of fluorinated oil: FC-40. Samples were aspirated as air-
segmented plugs into a piece of Teflon tubing by the force of a pulling syringe. The inner 
surface of the tubing was wet by FC-40. The tubing movement was controlled by an 
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XYZ-positioner (Figure 1-5). A linear ion trap was used for monitoring the intensity of 
the reaction product: choline. The inhibited reactions showed low intensity of choline 
while non-inhibited reactions showed similar intensity with the negative control (Figure 
1-6). This small screening proved that ESI-MS is amenable for HTS by employing 
segmented flow as sample introduction method. However, some improvement needs to 
be made: 1) air-segmented droplets are prone to coalescence when being pushed in the 
tubing due to the compressibility of the air; 2) the reagent consumption was high because 
reactions were conducted in a standard 96-well plate; 3) the salt-free buffer used in this 
AchE assay cannot be generalized because many proteins are only active in the buffers 
which may have ion suppression effect on ESI-MS. 
 
Figure 1-5. Diagram of reformatting acetylcholinesterase assays into air-segmented plugs. 
The array of sample plugs were prepared by dipping the tip of a 75 m i.d. Teflon tubing 
prefilled with Fluorinert FC-40 into sample solution stored in a multiwell plate, aspirating 
a desired volume, retrieving the tube, aspirating a desired volume of air, and moving to 
the next well until all samples were loaded. Movement of the tubing was controlled with 
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an automated micropositioner and sample flow was controlled with a syringe pump 
connected to the opposite end of the tubing.
41
 Reproduced with permission from Elsevier 
Inc..  
 
 
Figure 1-6. Screening of AchE inhibitors (in triplicates). The top droplet trace is the 
assay product choline, and the bottom one is the internal standard. Inset shows one mildly 
inhibited and one strongly inhibited reaction.
41
 Reproduced with permission from 
Elsevier Inc..  
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Replacing air with oil can address the coalescence issue. Perfluorinated oils are 
preferred in segmented flow because they are not compressible, and most compounds are 
insoluble in them.
28
 Our group has evaluated the compatibility of different perfluorinated 
oils with ESI-MS. The result showed that FC-40 and perfluorodecalin (PFD) do not 
generate signal at up to 1.5 kV in nanospray mode, and up to 3 kV in regular ESI mode.
42
 
PFD or FC-40 segmented droplets can be directly infused into ESI-MS without having 
interfering oil signals. In all experiments described in this dissertation, sample droplets 
were segmented by PFD. To reduce sample consumption, one can miniaturize the whole 
screening by conducting reactions inside droplets, or utilize high density MWPs. In this 
dissertation, both approaches are described (see screening workflow in Figure 1-7). A 
larger scale screening was performed with the second approach. To facilitate direct 
analysis of assays consisting of components that may disrupt ESI process, sample 
cleanup or sample dilution is required. Chapter 5 and 6 discuss the operation in details.  
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Figure 1-7. Flow charts for in-droplet screening (left) and high density MWP-based 
screening (right). 
 
Cathepsin B 
Cathepsin B belongs to the cathepsin family, which is a group of cysteine 
proteases of the papain family. They are predominantly endopeptidases which localize in 
Screen in droplets: 
Reformat test compounds in to a 
droplet array 
Inject reagents into each droplet to 
initiate reaction 
Incubate droplet-containing tubes 
Inject quenchant into each reaction 
droplet 
Infuse droplets into ESI-MS 
Screen in 384-well plates: 
Dispense reagents into 384-well plates 
to initiate reaction 
Incubate plates 
Dispense quenchant to each well   
Reformat quenched reactions into a 
droplet array 
Select hits 
Perform dose dependent experiments 
on selected hits 
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lysosomes of cells.
43
 Cathepsin B is a 30 kD protein. It is constitutively expressed for 
protein turnover. Functioning as an endopeptidase, cathepsin B prefers substrates with 
large hydrophobic side chains and two N-terminal residues to the hydrolysis site. 
Cathepsin B can also act as an exopeptidase which removes dipeptides from the C-
terminus of proteins and peptides.
44
 Cathepsin B is considered a potential therapeutic 
target because its relationship with several diseases has been established.
45
 The increase 
in expression of cathepsin B has been consistently found in human tumors, especially in 
epithelial cells of premalignant lesions.
46
 To date, the tumor proliferation, angiogenesis 
and metastasis in brain, lung, prostate, breast, and colon have been linked to cathepsin B 
overproduction.
47
 The expression of cathepsin B in such cancers are often positively 
correlated with a poor prognosis for patients.
48
 Inhibiting cathepsin B along with other 
cathepsins is able to retard the growth of pancreatic islet tumors in mice.
49
 Specifically 
inhibiting cathepsin B has been showed to reduce metastasis of murine breast cancer.
50
 
Aside from cancer, cathepsin B has been found to promote various viral infection 
diseases, including Ebola and SARS. It also plays a role in trematodes,
51
 rheumatoid 
arthritis
52
 and Alzheimer‟s disease53-55. With such broad implication with diseases, 
inhibition of cathepsin B is always considered to be holding great therapeutic potential. 
 
Sirtuins 
Sirtuins are a class of evolutionarily conserved nicotinamide adenine dinucleotide 
(NAD
+
)-dependent deacetylases, the expression of which are responsive to diet and 
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environmental stress. Human sirtuins include 7 members: SIRT1 to SIRT7. They control 
a wide range of cellular processes including gene silencing, regulation of p53, fatty acid 
metabolism, cell cycle regulation and life span extension.
56,57
 Last decade has witnessed 
growing attention towards sirtuins for their regulatory role in metabolism and aging. 
Numerous studies have been carried out to reveal the function of each individual sirtuin. 
The results are depicted in Figure 1-8.
56
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Figure 1-8. The sirtuin family‟s role in aging and age-associated pathologies. The sirtuin 
isoforms with substantial data indicating either a protective or aggravative role for 
specific age-related diseases are indicated.
56
 Reproduced with permission from The 
American Society for Clinical Investigation.  
 
SIRT1 is the most extensively studied sirtuin. It deacetylates various transcription 
factors and enzymes, hence regulates chromatin structure, transcription, apoptosis, 
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tumorigenesis, energy expenditure, and oxidative stress. It relieves metabolic dysfunction 
in numerous tissues, including liver, muscle, heart, and fat tissue (Figure 1-9).
56,57
 In 
vivo studies have proved that SIRT1 can prolong murine lifespan, suppress certain types 
of cancer, type 2 diabetes, neurodegenerative diseases, and many other aging-related 
diseases.
56,58-60
  
 
Figure 1-9. SIRT1 mediates metabolic benefits in various tissues, such as liver, heart, 
white adipose tissues (WAT), and skeletal muscle. In general, SIRT1 supports 
gluconeogenesis, inhibits glycolysis, promotes fatty acid oxidation, regulates cholesterol 
homeostasis, and protects against cardiac hypertrophy. Targets that directly activated by 
SIRT1 are shown in green, and those inhibited are in pink.
57
 Reproduced with permission 
from Elsevier Inc.. 
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Because of the promising therapeutic value of SIRT1 activation, people have 
passionately searched for SIRT1 modulators. A series of SIRT1 activating compounds 
(STACs) were discovered based on a fluorescent screening. The activation mechanism is 
promoting substrate-protein binding. Most of the STACs are plant-based polyphenols, 
including resveratrol, a molecule found in red wine. In the fluorescent assay, the synthetic 
fluorogenic peptide substrate is sensitized to fluorescence developer after being 
deacetylated by SIRT1 (Figure 1-10). The developed fluorophore indicates the level of 
deacetylation.
59
  Corroborating the finding is considerable amount of studies that showing 
improved metabolic syndrome by STACs.
60-66
 However, further investigation of the 
activation mechanism revealed that STACs indeed enhance the binding and deacetylation 
of the fluorogenic substrate, but exert no effect on native peptides.
56,67-70
 Although later 
studies have argued that the bulky, hydrophobic fluorophore activates SIRT1 
allostercially,
71,72
 which might mimic hydrophobic moieties of certain natural substrates, 
the true relations between STACs and SIRT1, and their beneficial effect in aging-related 
diseases are still under debate. 
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Figure 1-10 Fluor de Lys
®
 fluorescent assay: the Fluor de Lys
®
 SIRT1 Substrate, which 
contains a peptide comprising amino acids 379-382 of human p53 (Arg-His-Lys-Lys(Ac)) 
is deacetylated by SIRT1 at present of NAD
+
. Treating with the Fluor de Lys
® 
Developer 
II, the deacetylated peptide produces a fluorophore (http://www.enzolifesciences.com). 
 
Sirtuin 6 (SIRT6) is predominantly localized inside the nucleus and associated 
with the chromatin. It was initially categorized as a mono adenosine diphosphate (ADP) 
ribosyl transferase.
73
 In 2008, the deacetylation of histone H3 lysine 9 (H3K9(Ac)) by 
SIRT6 was discovered. This activity was proposed to contribute to the telomere 
protection capability of SIRT6.
74
 Later, another substrate, histone H3 lysine 56 
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(H3K56(Ac)) was confirmed. Deacetylation of H3K56(Ac) is also linked to maintaining 
the stability of telomeric chromatin during cell cycle.
73
 In 2012, researchers noticed that 
SIRT6 overexpression can extend the lifespan of male mice. It has been the first direct 
relationship between sirtuins and longevity.
75
 The comprehensive interrogation of all 
possible functions of SIRT6 has been carried out ever since. Increasing evidence shows 
that SIRT6 participates in a variety of cellular pathways by deacetylating a broad 
spectrum of post translational modifications: it stabilizes DNA in most tissues, especially 
in liver, heart and muscle; it helps maintain normal glucose homeostasis; it reduces cell 
apoptosis and senescence by deacetylating NF-B; it suppresses cancer initiation but on 
the other hand helps the survival of already-formed tumors;
76
 it controls partitioning 
circadian transcription,
77
 and so on (Figure 1-11). 
 
Figure 1-11. SIRT6‟s substrates and physiological impact.76 Reproduced with permission 
from Springer Publishing. 
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Intrigued by the broad sphere of health benefits (though conflicting effects exist), 
the search for SIRT6 modulators have been attempted recently
76
. However, due to the 
low deacetylation activity, it is hard to develop a reliable SIRT6 assay, thus very few 
valid modulators have been established. In 2013, one research group reported that SIRT6 
can hydrolyze an endogenous long-chain fatty acylated protein (lysine 19 and lysine 20 
on TNF-) with high efficiency. Later, they found that this deacylation activity is 
independent on the protein sequence.
78
 Based on this breakthrough discovery, another 
research group found that the low deacetylation activity of SIRT6 can be elevated by 
fatty acids, which are the first type of SIRT6 activators being reported. And such 
activation effect is exclusively in SIRT6 (Figure 1-12).
79
 Very recently, SIRT6 
modulator screenings based on fluorogenic assays using H3K56 and myristoylated 
peptide as substrates have been published, a handful of common sirtuin inhibitors were 
proved to slightly inhibit SIRT6.
80,81
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Figure 1-12. Sirtuin activity in the presence of free fatty acids. Fold change in SIRT1 and 
SIRT6 deacetylase activity was monitored in the presence of various fatty acids and 
compared to a reaction without fatty acid. SIRT1 (dark gay) and SIRT6 (light gray) were 
incubated with 70 µM H3K9Ac peptide and 0.5 mM NAD
+
 in the presence of 100 µM 
fatty acid and analyzed by HPLC.
79
 Reproduced with permission from American Society 
for Biochemistry and Molecular Biology. 
 
Dissertation Overview 
The research presented in this dissertation aims at elaborating the work previously 
accomplished by the Kennedy group. Droplet-ESI-MS system is a novel high throughput 
screening platform. Efforts have been made to miniaturize a screening by conducting 
reactions inside droplets through microfabricated reagent addition chips; hyphenate the 
system with well-established, commercially available, MWP-based high throughput 
screening workflow; develop three enzymatic assays which can be directly analyzed by 
ESI-MS with minimum sample preparation; apply the miniaturized all-droplet system and 
integrated MWP-to-droplet system to enzyme modulator screenings. 
Chapter 2 discusses the potential to reduce reagent use by performing enzymatic 
assays inside nanoliter level droplets. In this work, we developed an all-droplet system 
coupling to ESI-MS which realized rapid label-free cathepsin B inhibitor screening with 
ultralow sample consumption and a superb Z-factor (~ 0.8). Multistep reactions were 
carried out inside 100 test compound droplets of 8 nL each and the result was analyzed 
by ESI-MS at up to 0.77 Hz. Microfabricated PDMS tees were used for adding the 
enzyme, substrate and quenchant into the droplets array for each step. Teflon tubes were 
used as storage and incubation vessels. By using this all-droplet system, 0.8 picomoles of 
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each test compound, 1.6 picomoles of substrate and 5 femtomoles of enzyme were 
consumed per reaction, which was ~10000-fold less than a MWP-based approach. This 
work was published on Analytical Chemistry in 2012.
82
 
Chapter 3 presents a work integrating the droplet-ESI-MS scheme to MWP-based 
high throughput screening workflow. We developed a „MS Plate Reader‟ which coupled 
standard MWP-based HTS workflow to droplet ESI-MS. The MS plate reader can 
reformat 3072 samples from eight 384-well plates into nanoliter droplets segmented by 
an immiscible oil at 4.5 samples/s and sequentially analyze them by MS at 2 samples/s. 
Using the system, a label-free screen for cathepsin B modulators against 1,280 chemicals 
was completed in 45 min with a high Z-factor (> 0.72) without a false positive (24 of 24 
hits confirmed). The assay revealed 11 structures not previously linked to cathepsin 
inhibition. For even larger-scale screening, reformatting and analysis could be conducted 
simultaneously, which would enable more than 145000 samples to be analyzed in one 
day. This work was published on Analytical Chemistry in 2014.
83
 
 Chapter 4 discusses the development of an ESI-MS-compatible SIRT1 assay. The 
assay is suitable for high throughput modulator screening. To enable direct ESI-MS 
analysis, SIRT1 was dialyzed into a buffer which does not affect the MS analysis of any 
molecules, and the deacetylation reaction was conducted in such buffer. The reaction 
yield was comparable to using the traditional Tris buffer. The assay conditions were 
optimized by enzyme kinetic studies, and validated by an 80-compound library screening. 
The high Z-factor (0.7) and high confirmation rate (all 4 inhibitor hits confirmed) indicate 
a reliable assay.  
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Chapter 5 shows that the droplet-ESI-MS system can be applied to another 
enzyme: SIRT6. Two SIRT6 assays were developed using two different substrates. 
Because for substrate H3K9(Ac), the activity of SIRT6 is low in most MS-compatible 
buffers, we ran the reaction in the original Tris buffer and then diluted the mixture to the 
extent that buffer components have little ion suppression effect on the reaction product, 
and the product is not too diluted for a quantifiable measurement. A test screen showed 
reliable quantification for this dilution approach. The standard deviation of negative 
control was low, and the known activator was identified. Aside from that, we confirmed 
that screening without replicates can yield similar results with a triplicated one. Though 
the analysis rate for each droplet decreased from 2 Hz (maximum rate) to 1 Hz for a more 
reliable readout, reducing the number of droplets for each reaction by 2/3 ended up with 
33% improvement in the overall throughput. SIRT6 hydrolyzes another substrate 
H3K9(decanoyl) with high efficiency. For that, we elected to use similar MS-compatible 
condition described in Chapter 4. A SIRT6 deacylation assay was also developed for 
large-scale droplet-ESI-MS-based screening. 
Chapter 6 discusses the possible improvement for current systems, including 
reducing the carryover of reagent addition chip, scaling up the screening using all-droplet 
system, fully automating MS plate reader, integrating sample cleanup in to droplet-ESI-
MS, tracking a screen, and developing custom data analysis software. 
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CHAPTER 2 
LABEL FREE SCREENING OF ENZYME INHIBITORS AT FEMTOMOLE 
SCALE USING ALL-DROPLET-ELECTROSPRAY IONIZATION-MASS 
SPECTROMETRY SYSTEM 
 
Introduction 
Droplet-based microfluidics has emerged as a powerful tool for analysis of low 
volume samples.
84,85
 In this approach, samples are compartmentalized within an 
immiscible fluid that is manipulated within a microfluidic channel or tube. This 
technology is descended from continuous flow analysis,
86
 commonly used for automated 
analysis prior to multi-well plates (MWP) and flow injection analysis. When droplets are 
large enough to span the walls of the channel, they form plugs and the resulting system is 
referred to as segmented flow. Droplets can be moved through a microfluidic system by 
pressure-induced flow where operations such as reagent addition,
32,87,88
 dilution,
33 
splitting,
31,89
 or sorting
90,91
 may be performed. A variety of chemical measurements 
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including enzymatic activity,
41,92,93
 enzyme kinetics,
94-97
 and cell-based assays
98-100 
have 
been developed for droplet format. 
Salient features of droplet systems are their small sample volumes (picoliter to 
nanoliter volumes are typical) and high throughput (e.g., reagents can be added to 
segmented samples at rates as high as 10 Hz
27
).  These properties make droplet 
microfluidics attractive for screening applications. The small scale can greatly reduce 
cost of reagents compared to screens performed at microliter volumes in MWP while the 
high speed enables the necessary throughput. Droplet microfluidics have been used for 
screening for engineered proteins,
30
 protein crystallization,
36
 and reaction catalysts.
101
  
Most chemical measurements in droplets have relied on optical detection such as 
fluorescence or colorimetric changes. While such methods are powerful and rapid 
(allowing analysis at up to kilohertz rates
30
), they are restricted to single component 
detection unless wavelength resolution is used. More importantly, they require 
engineering an optical change into the reaction being screened by use of either labels or 
coupled reactions. Incorporation of optical properties can slow investigation of a new 
target and in some cases may not be feasible. Even when feasible, labels can affect the 
reaction being studied, generate false signals,
102
 and add expense to the screen because of 
increased reagent cost. For these reasons, label-free screening is desirable.
6,7,102
 
A potentially powerful method for label-free screening at droplet scale is mass 
spectrometry (MS). In one study, segmented samples were deposited onto a plate for 
matrix-assisted laser desorption ionization (MALDI)-MS analysis.
34
 This approach 
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allowed optimization of a deacetylation reaction using just 20 g of substrate illustrating 
the feasibility of screening at reduced scale. Electrospray ionization (ESI) would be a 
valuable complement to MALDI methods. Several techniques for interfacing droplets to 
ESI-MS have been reported.
38-40,103
 Methods involve either extraction of droplets into a 
stream that flows to the ESI source or directly passing the segmented stream into the ESI 
source. While either approach may be used, we favor the latter because it is simple and 
allows samples to remain encapsulated up to the point of detection to avoid dilution and 
reduce potential for carry-over. Segmented flow ESI-MS has been used to monitor 
chemical reactions
103
 and for analysis of fractions collected from capillary LC columns.
42
 
It has also been used to screen an enzymatic reaction that did not involve a color change 
(acetylcholinesterase catalyzed hydrolysis of acetylcholine
41
). In that study however, the 
reaction was performed in MWP-scale and then reformatted for segmented flow, 
therefore miniaturization of the reaction was not realized. 
In this work we seek to demonstrate the potential for label-free screening of 
reactions at nanoliter scale using segmented flow ESI-MS. The system is tested using 
Cathepsin B catalyzed proteolysis as a model reaction. Inhibitors of this protein are of 
interest for treatment of Alzheimer‟s disease,104 various types of cancer,105 arthritic 
disease,
106 
and trematode infection.
107
 This enzyme is presently screened using a 
fluorogenic substrate, nevertheless it provides a useful test case for segmented flow ESI-
MS.       
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Experimental Section 
Chemicals and Materials. Unless otherwise specified, all solvents were 
purchased from Honeywell Burdick & Jackson (Muskegon, MI) and were certified ACS 
grade or better. All reagents were purchased from Sigma Aldrich (St. Louis, MO). 
Droplet Generation from MWP. Oil-segmented sample droplets were generated 
by sampling from a MWP using a protocol described previously (Figure 2-1).
40
 Samples 
were pulled into a 150 m i.d. × 360 m o.d. Teflon tube (IDEX Health and Science, Oak 
Harbor, WA) connected to a 100 L Hamilton syringe (Fisher Scientific, Pittsburgh, PA) 
mounted on a PHD 200 programmable syringe pump (Harvard Apparatus, Holliston, 
MA). The syringe and Teflon tube were pre-filled with perfluorodecalin (PFD, 95% 
purity, Acros Organics, NJ). To fill the tube with oil-segmented droplets, a computer-
controlled XYZ-positioner (built in-house from XSlide assemblies, Velmex Inc., 
Bloomfield, NY) was used to move the inlet of the Teflon tube from sample to sample on 
the MWP while the syringe was withdrawing at 150-180 nL/min. The samples were 
covered with PFD to prevent aspiration of air as the tube moving from sample to sample. 
(The edges of the MWP were built-up to 3 mm height using epoxy to hold PFD over the 
wells.) Droplets with 5 to 15 nL volume separated by 10-20 nL oil were produced by 
controlling the time that the tube dwelled in sample or oil. The relative standard deviation 
(RSD) of droplet size was < 5%.  
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Figure 2-1 A) Diagram of oil-segmented droplet generation from a MWP. The XYZ-
positioner causes the Teflon tube to dwell in sample or oil for predetermined time, and 
then move to another well. The syringe pump operates in refill mode at a constant flow 
rate. B) Diagram of ESI-MS analysis of sample droplets. The syringe drives droplets into 
the ESI source through a Pt-coated emitter. +1.7 kV is applied on the emitter. 
 
MS Analysis. Teflon tubes containing segmented samples were connected to a 75 
m i.d. Pt-coated fused-silica electrospray emitter (FS-360-75-30-CE, New Objective, 
Woburn, MA) pulled to 30 m i.d. at the tip (Figure 2-1B). The emitter was mounted 
onto the nanospray source of the mass spectrometer. A syringe pump (Fusion 400, 
Chemyx, Stafford, TX) operated from 0.75 to 1.8 L/min drove sample droplets through 
the emitter. PFD emerging from the tip was siphoned away using a Teflon tube placed 
near the tip as described before.
42
 ESI voltage of +1.7 kV was directly applied to the 
A 
 
 
 
 
 
 
 
 
B 
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emitter. MS analysis was performed with a LTQ XL linear ion trap MS (Thermo Fisher 
Scientific, Waltham, MA) operated in positive mode, scanning from 350-690 m/z in 0.1 s. 
Extracted ion currents (XICs) of assay components were used for analysis. Peak detection 
was performed using Qual Browser (Version 2.0, Thermo Electron Co.).  
In-well Cathepsin B Inhibitor Screening. Cathepsin B assays were initially 
tested by performing the reactions in vials or wells and then formatting for segmented 
flow. These assays used carboxybenzyl-Arg-Arg-7-amido-4-methylcoumarin (ZRR-
AMC) as substrate and were modified from previous reports.
108
  
First, the calibration curve of the standard assay product (ZRR-OH, > 99%, 
custom synthesized by AnaSpec Inc., Fremont, CA) is obtained in the range from 10 M 
to 180 M. Solutions were prepared in 20% (v/v) methanol and 0.2% (v/v) acetic acid. 
Different solutions were made into plugs and directly infused into MS. The relative signal 
abundance (relative peak height) of each sample was used for analyzing how MS 
response is related to sample concentration. A linear relationship was obtained with R
2 
= 
0.991. In addition, no obvious ion suppression between analytes was observed in our 
experiment. The signal of the assay product was always reversely related to that of the 
substrate, and both of them were not affected by either samples or byproducts. All 
experiments were done in this calibration range (Figure 2-2).  
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Figure 2-2. Calibration curve for ZRR-OH. 10 solutions of ZRR-OH with concentration 
as 10, 20, 40, 60, 80, 100, 120, 140, 160, 180 M were formatted as sample plugs and 
driven into ESI-MS for analysis. The ESI conditions were same with all other 
experiments. Using the relative abundance of each peak, the calibration curve had slope 
of 0.56, y-intercept of -3.6443, R
2
 of 0.9912. 
 
Second, the assay conditions were tested by the dose response experiments of 
three known inhibitors of Cathepsin B: E-64 (L-trans-3-carboxyoxiran-2-carbonyl-L-
leucylagmatine), Leupeptin (acetyl-Leu-Leu-Arg-al N-Acetyl-L-leucyl-L-leucyl-L-
argininal), and Antipain ([(S)-1-Carboxy-2-phenylethyl]carbamoyl-L-arginyl-L-valyl-
argininal) were prepared in a series of aqueous solutions whose concentration ranged 
from 10
-7
 M to 103 M to obtain the dose response relations with Cathepsin B. The final 
concentration of the substrate ZRR-AMC was 180 M and Cathepsin B 8.1 g/mL. The 
quenched reaction mixtures were analyzed using relative abundance of ZRR-OH in its 
XIC. The results showed sigmoidal relationship between the concentration of the 
inhibitor and the relative signal intensity of ZRR-OH produced. The IC50s of three 
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inhibitors under our specific experiment conditions were generally agreed with reported 
values (E-64: 55 nM, leupeptin: 21.3 nM, antipain 0.98 M, Figure 2-3) 
 
Figure 2-3. Dose response curves of three known inhibitors determined by droplet-MS. 
Different concentrations of E-64 (10
-7
, 10
-4
, 10
-3
, 10
-2
, 0.1, 0.3, 1, 2, 3, 10, 100 ,1000 M), 
Leupeptin  (10
-7
, 10
-4
, 10
-3
, 0.1, 0.3, 1, 2, 3, 10, 100 ,1000 M), Antipain (5×10-7, 5×10-5, 
5×10
-4
, 5×10
-3
, 5×10
-2
, 0.5, 1.5, 3, 5, 10, 15, 50, 500 ,5000 M) were incubated with 
ZRR-AMC and the enzyme. Relative abundance of ZRR-OH peaks were used for 
construct the sigmoidal curves. 
 
24 test compounds, including three known Cathepsin B inhibitors: E-64, leupeptin 
and Antipain were dissolved in water at 200 M. (See Appendix A for other test 
 37 
 
compounds.) 50 L of each test compound solution was mixed with 30 L of 27 g/mL 
bovine spleen Cathepsin B and 200 M 1,3-dithioerythritol (DTE) in 20 mM ammonium 
formate buffer at pH 6.7 and incubated for 5 min at room temperature. 18 L of substrate 
1 mM ZRR-AMC in water was then added to start turnover. After 10 min of incubation 
in a 40 
o
C water bath, 20 L of a quenchant consisting of 98% methanol and 2% acetic 
acid (v/v) was rapidly added. 80 L of each quenched reaction mixture was pipetted into 
a 384-well plate (Axygen Scientific, Union City, CA). 96 sample droplets (4 from each 
reaction mixture) of 11 nL each were generated using the procedure described above and 
pumped into MS at 0.75 L/min through a Pt-coated emitter. XICs of the product 
carboxybenzyl-Arg-Arg (ZRR-OH) were used for analysis. 
In experiments using unlabeled peptide Ac-GFGFVGG-NH2 (American Peptide 
Company Inc., Sunnyvale, CA) as substrate, the procedures were the same except that 
test compounds were prepared at 40 and the enzyme 54 g/mL. Each reaction 
mixture was made into 14 nL of droplets, in quintuplicate. XICs of the product FVGG-
NH2 (m/z 378.5) were used for analysis. 
All-droplet Cathepsin B Inhibitor Screening. To perform the assay reaction in 
droplets, test compounds were prepared as a 100-droplet array (8 nL each) consisting of 4 
droplets for each of 25 test compounds at 100 M. Droplets were prepared with a 16 nL 
oil plug between them and loaded into a 150 m i.d. x 360 m o.d. Teflon tube. 
Cathepsin B (54 g/mL), ZRR-AMC (600 M), and quenchant were added to the test 
compound droplets in sequence using PDMS tees. (See Appendix A for test compounds.) 
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Droplets were pumped into the inlet channel of the tee at 2 L/min while solution to be 
added was pumped in an orthogonal channel at 200 nL/min. The resulting droplets exited 
the outlet channel and were collected into a Teflon tube. Cathepsin B solution was 
injected into the droplets first and required 1 min for 100 sample droplets. Substrate was 
then added and the resulting tube of droplets was sealed with Sticky Wax (KerrLab, 
Orange, CA) and placed into a 40 
o
C water bath for 15 min. After incubation the ends of 
the tube were trimmed off and quenchant was added. The final droplets containing 
quenched reaction solutions were infused into the MS at 1.5 L/min.  
In other experiments, native substrate was used with a Teflon tee.
109
 5 nL of 80 
M test compounds were loaded into the Teflon tube with 10 nL plugs of oil between 
them. Enzyme (108 g/mL), substrate (600 M) and quenchant were added using the 
same flow rates. Resulting droplets were pumped into the MS at 0.75 L/min.  
PDMS Tee Fabrication. Polydimethylsiloxane (PDMS) reagent addition tees 
were fabricated using soft lithography.
110
 The droplet channel was rendered hydrophobic 
by silanization immediately after plasma bonding by pumping 1:100 (v/v) 
trichloro(1H,1H,2H,2H-perfluorooctyl) silane solution in anhydrous hexadecane through 
it (Figure 2-4). A 3 cm length of pre-silanized 50 m i.d. x 150 m o.d. fused silica 
capillary (Polymicro Technologies, Phoenix, AZ) was inserted from the side of the tee 
into the droplet inlet channel, and a 6 cm length of non-derivatized 20 m i.d. x 150 m 
o.d. capillary was inserted into the reagent channel. A 3 cm length of 150 m i.d. x 360 
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m o.d. Teflon tube was inserted into the outlet channel. Capillaries and the Teflon tube 
were glued over the ends with 5 minute Epoxy (Devcon, Danvers, MA).  
 
Figure 2-4. Illustration of fused silica surface derivatized by trichloro(1H,1H,2H,2H-
perfluorooctyl) silane. 
 
Carry-over measurement. Carry-over of the spray emitter was measured by 
pumping alternating sample/blank droplets (sample droplets contained 200 M ZRR-OH 
dissolved in 20% methanol and 0.2% acetic acid ESI buffer, blank droplets only 
contained the buffer) through the emitter tip to ESI-MS. The signal intensity of each 
droplet was used for analysis. < 1% carry-over occurred in the spray emitter, which was 
in agreement with previous results
40
 (Figure 2-5A). Carry-over of the PDMS tee for one 
addition was measured by adding quenchant (98% methanol and 2% acetic acid) into 10 
nL alternating sample/blank droplets (the sample was 200 M ZRR-OH water solution, 
and the blank is water), where we observed ~ 9% of carry-over. 2 additions were 
conducted by adding water, and then adding quenchant into the same alternating droplets. 
B
 40 
 
The carry-over increased to 16% with 2 additions. In results of the real screening, 3 
additions led to more than 25% of carry-over (Figure 2-8).  
We also measured the carry-over of the Teflon tee for one addition. Same 
quenchant was added into alternating droplets in which sample droplets contained 200 
M Ac-GFGFVGG-NH2 and blank droplets contained water. The carry-over could be as 
low as 2% (Figure 2-4B). 
 
A 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
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Figure 2-5 A) Carry-over of the all-droplet system. <1 % of carry-over was observed in 
the emitter (upper left). 9% of carry-over was generated by the tee for one addition (upper 
right) and 16% for two additions (lower left). The carry-over of three addition is 25-30% 
(lower right). B) Carry-over of the Teflon tee for one addition. 
 
Results and Discussion 
In-well Cathepsin B Inhibitor Screening. Cathepsin B is commonly screened 
using the fluorogenic substrate ZRR-AMC by the reaction shown in Figure 2-6A. By 
performing the reaction in a low concentration buffer (6 mM ammonium formate and 60 
DTE) and quenching the reaction with 98% methanol and 2% acetic acid, both the 
substrate and product can be readily detected by ESI-MS. These results suggest that the 
buffer conditions are both suitable for retaining enzymatic activity and are MS friendly. 
Although a fluorescent substrate for Cathepsin B has been devised, the MS can also 
detect native substrates. To demonstrate this we synthesized the non-fluorescent 
heptapeptide Ac-GFGFVGG-NH2 that should serve as a good substrate according to 
previous studies on the selectivity of this enzyme.
111,112
 The reaction and mass spectrum 
of the reaction mixture illustrating detection of substrate and product (FVGG-NH2) are 
shown in Figure 2-6B. These results illustrate the potential of ESI-MS for detecting 
different substrate-product pairs, reactions of unlabeled substrates, and for detecting 
substrate and product simultaneously as long as reaction conditions are enzyme and ESI-
MS compatible. 
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Figure 2-6. A) Cathepsin B catalyzed proteolysis of ZRR-AMC and ESI mass spectrum 
of resulting reaction mixture. B) Cathepsin B catalyzed proteolysis of Ac-GFGFVGG-
NH2 and ESI mass spectrum of reaction mixture. 
 
We then tested both assays in a screening format. Reaction solutions were 
reformatted to segmented flow from a MWP, and then analyzed by ESI-MS. The result of 
screening 24 test compounds (one negative control, three positive controls and 20 
randomly chosen small molecules as potential inhibitors) in quadruplicate using the 
substrate ZRR-AMC is illustrated in Figure 2-7A. The result of a similar experiment 
using 12 samples in quintuplicate using unlabeled peptide substrate is shown in Figure 2-
7B.  Each droplet is detected as a burst of current separated by low signal that 
corresponds to oil exiting the emitter nozzle. As shown previously, PFD does not spray or 
generate signal under these conditions.
42
 Each sample current burst consists of a series of 
mass spectra (~10 spectra for each droplet) so that different m/z channels can be 
simultaneously monitored allowing detection of the substrate, product, and inhibitors. 
A 
 
 
 
 
B 
A 
 
 
 
 
B 
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The impact of inhibitors on the enzyme is evident in low signal intensity for product 
when inhibitors are present. The assay has good reproducibility with RSD < 3% in 
droplet peak height each test compound set. The MS detection is also rapid with the 
throughput of 0.66 Hz.  
 
Figure 2-7. A) Result of in-well screening of Cathepsin B inhibitors using ZRR-AMC as 
the substrate. XICs show signal for ZRR-OH and the known inhibitors E-64, leupeptin, 
and antipain. Each of 24 reaction mixtures was formatted in quadruplicate. Droplets with 
A) 
 
 
 
 
 
 
 
 
 
 
 
 
 
B) 
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low product signal are inhibitor sets. B) Result of screening using Ac-GFGFVGG-NH2 as 
the substrate. XICs are product FVGG-NH2 and the substrate. 12 reaction solutions were 
formatted in quintuplicate. 
 
The suitability of the assay for screening was evaluated using Z-factor.
113
 Z-factor 
is a statistic defined as Z = 1- 3× (pos+neg)/(pos-neg), where pos and neg represent the 
SD of the response in positive and negative control, and pos and neg are the mean 
response of each. Z-factor exceeding 0.5 is considered suitable for HTS. In our 
experiment, Z-factors were 0.92 (E-64), 091 (leupeptin), and 0.91(antipain) for the 
fluorescent substrate, and 0.93 (E-64), 0.93 (leupeptin), and 0.70 (antipain) for the 
unlabeled substrate.  
The assays can also provide quantitative characterization of the reaction. A linear 
relationship between sample concentration and relative signal intensity was obtainable 
from 10 M to180 M (R2 = 0.991). IC50s of three inhibitors determined from dose 
response analysis under our experiment conditions generally agreed with reported values. 
These results illustrate that each reaction result can be rapidly analyzed at nanoliter scale 
by segmented flow ESI-MS and that the results are suitable for screening and quantitative 
assay of inhibitors.  
All-droplet Cathepsin B Inhibitor Screening. With the assay established, we 
sought to miniaturize the system to take advantage of the small quantities used for actual 
detection of segmented flow ESI-MS.  To do so, we performed the entire Cathepsin B 
inhibitor screen in an all droplet format (Figure 2-8A). In this approach, 25 test 
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compounds were first formatted as droplets (8 nL each, in quadruplicate) in a tube. The 
droplets were then pumped through a series of reagent addition tees where 2-3 nL of 
enzyme, substrate, and quenchant could be added for each step. The final droplet size was 
about 16 nL. Fixing the droplet flow rate at 2 L/min, one reagent addition was 
completed at 1.4 Hz. 100 droplets were analyzed in 2.2 min (0.8 Hz), as illustrated in 
Figure 2-8B.  
 
A 
 
 
 
 
 
 
 
 
 
 
 
B 
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Figure 2-8. A) Diagram of all-droplet screening system coupled to ESI-MS analysis. Test 
compounds arrayed as droplets were pumped into a series of PDMS tees where enzyme, 
substrate, and quenchant were added in. (For the actual experiment, the third Teflon tube 
was sealed on both ends and incubated in a water bath prior to pumping droplets through 
the quenchant addition tee.) The inset is a photomicrograph of the PDMS tee. The droplet 
inlet is silanized 50 m i.d. × 150 m o.d. capillary, the outlet is 150 m i.d. × 360 m 
o.d. Teflon tube, and the reagent channel is non-derivatized 20 m i.d. × 150 m o.d. 
capillary. B) Results of all-droplet screening using ZRR-AMC as the substrate. XICs are 
ZRR-OH, antipain, E-64, and leupeptin. Each test compounds has 4 replicates. 
 
XICs of the assay product ZRR-OH allowed easy detection of inhibitors and non-
inhibitors. Some carry-over was observed in that signal of the first droplet of each 
inhibitor set was higher than the rest. Also, signal for the first droplet of non-inhibitor 
was lower than its replicates if following an inhibitor, as pointed out in Figure 2-8B. To 
avoid the impact of carry-over, RSD and Z-factors were calculated using the signal 
intensity of the 2
nd
-4
th
 droplet of each set. The RSD was 11% on average, which was 
larger than in-well screening due to the higher throughput which compromised the 
number of data points for each droplet, and the accumulation of the slight variation in 
each reagent addition. The Z-factors were 0.82, 0.85, and 0.76 for E-64, leupeptin, and 
antipain, respectively. For each reaction, 1.6 picomoles of ZRR-AMC, 0.8 picomoles of 
test compound, and 5 femtomoles of Cathepsin B were consumed. This represents a 
10,000-fold reduction compared to the in-well assay. Further, in droplet screening these 
amounts used can be achieved with no waste or requirements for larger reservoirs of 
compounds. 
For these experiments, we used the reagent addition tee shown in Figure 2-8A. 
The geometry of the tee was designed to avoid formation of reagent-only droplets 
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between sample droplets. As reagent continuously flows out of the reagent capillary, the 
interfacial tension between water and PFD prevents it from being detached from the end 
of the channel. When an aqueous droplet arrives at the junction, it merges with the 
accumulated reagent and flows away from the tee. However, if oil gaps between droplets 
are too long, or the reagent flow rate is too high, reagent droplets may form and be swept 
off by the oil. The results of having reagent-only droplets include irreproducible addition 
ratio, non-uniform droplet train, and uneven pressure, all of which are detrimental to 
multistep reactions. As described elsewhere, a larger outlet prevents reagent-only droplet 
formation effectively.
114
 Indeed, no unexpected signal was detected between droplets 
(Figure 2-8B) showing that this design effectively prevented reagent-only droplets.  
Carry-over and Alternative Reagent Addition Device. Although the all-droplet 
system was effective in many ways, we further studied it to determine if improvements 
were possible. Our carry-over measurement showed that < 1% of carry-over was caused 
by the emitter, in agreement with previous results.
41
 One reagent addition using the 
PDMS tee resulted in ~9% of carry-over, which increased to 16% with 2 additions and 25% 
with 3 additions. This carry-over appears to be related to the low Péclet number (ratio of 
advection rate to diffusion rate) developed in the tee. Advection facilitates merging while 
diffusion causes contamination during reagent addition.
115
 The broad outlet of the tee 
slows down the reagent that prevents reagent-only droplets from forming, but it also 
slows down the passing droplet that leads to longer diffusive mixing of sample and 
reagent at the junction. Commonly carry-over is circumvented by inserting a “rinse” 
droplet between samples.
34
 We achieved a similar effect here by running samples in 
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quadruplicate and discarding the first sample of each set. The carry-over of the 2
nd
 blank 
droplets was < 6%, even after 3 additions, which did not affect the Z-factor.  
Using replicate droplets is effective and easy to implement. It also adds little time 
to a small scale screen. However, for large screens it would be desirable to avoid the 
carry-over completely to minimize the time spent rinsing between samples. We therefore 
evaluated a Teflon tee.
109
 This tee yielded approximately 2-5% carry-over per reagent 
addition (Figure 2-5B.) The raw trace for assay product FVGG-NH2 from a small-scale 
screen with the non-fluorescent substrate is shown in Figure 2-9. The total carry-over in 
the 1
st
 droplet was 10-14% and negligible in following droplets. The low carry-over of 
the Teflon tee can be attributed to (1) a narrow outlet that allowed relatively high velocity 
through tee; (2) partial coverage of the reagent outlet by Teflon that prevents droplets 
from sticking to the capillary. Both tees were demonstrated as good reagent addition 
devices for this application. Other tee designs have been reported to yield low carry-over 
and high addition ratio that may produce even better results.
32
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Figure 2-9. A) Photomicrograph of Teflon tee. The droplet channel is 150 m i.d. × 360 
m o.d. Teflon tube. The reagent channel is 40 m i.d. × 190 m o.d. non-derivatized 
capillary. B) Trace resulting from all-droplet screening with the Teflon tee using the non-
fluorescent substrate. XIC is the product FVGG-NH2. Samples were run in quintuplicate. 
 
Throughput. The emphasis in this work is on miniaturizing label-free enzyme 
assays. This miniaturization should be valuable when protein target or reagents are 
difficult or expensive to obtain. Miniaturization is also beneficial in scale-up of a screen. 
The biggest expense of large scale screens is often reagents,
34 
so reduction of volume can 
make screens more affordable. Droplet assays also have potential utility in high-
A 
 
 
 
 
 
 
 
 
 
 
 
B 
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throughput screening. For the all droplet-assay, the steps to completing a screen are: (1) 
droplet generation, (2) all-droplet reactions, (3) MS analysis. In this experiment around 
10 min is required to load 96 droplets using the XYZ-positioner; however, faster 
positioners and parallel operation can greatly reduce this time. Further, it may be feasible 
to reformat libraries to droplets before they are needed thus eliminating this time for a 
screen. Reagent addition was performed 1.4 samples/s, which was comparable with other 
studies; although rates up to 10 Hz have been reported.
27
 The reactions themselves 
require 15-20 min incubation. This time cannot be eliminated; however, if the fluidics is 
operated in a steady stream then after an initial lag time samples would be produced at a 
rate limited by the reagent addition rate. Alternatively, tubes could be prepared in parallel 
and reactions could be done in batch. Finally, the ESI-MS rate was 0.5 to 1 Hz here and 
faster rates may be possible with a faster scanning MS.  
 
Conclusion 
A label-free all-droplet assay system was developed in this work. Its robustness, 
ultralow reagent consumption, and high throughput were demonstrated by the screening 
of Cathepsin B inhibitors. Compared with MWP-based fluorescence assay systems, this 
approach eliminates the need of labeling and reduces the sample requirement over 1000-
fold. These results suggest the potential for screening reactions for optimization, 
chemical probe discovery, and drug discovery, especially when reagent or protein target 
are expensive or difficult to obtain. Further development is required for routine high-
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throughput screening. One limitation of the system is the built-up of carry-over in a 
multi-step reaction. Modifications of the tee such as changing the dimension of the 
channels will be explored in order to reduce the carry-over. In pursuit of higher 
throughput, parallel droplet generation, parallel droplet-based reactions and faster mass 
spectrometer may be incorporated.   
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CHAPTER 3 
DROPLET-ELECTROSPRAY IONIZATION-MASS SPECTROMETRY FOR 
LABEL FREE HIGH THROUGHPUT SCREENING FOR ENZYME 
INHIBITORS 
 
Introduction 
High throughput screening (HTS) is important in drug discovery, chemical 
biology, and chemistry. Current technology relies mostly on performing reactions in 
multi-well plates (MWP) with robotic manipulation of fluids followed by interrogation 
using optical plate-readers.
1,2
 Mass spectrometry (MS) is a potentially powerful technique 
for HTS because it is fast, has high resolution, and can detect chemicals without 
labels.
7,102
 This latter advantage is important because it eliminates false signals based on a 
label or indicator reaction and avoids the time, expense, and expertise needed to modify 
target compounds for optical assay. Use of MS in screening
3,116-118
 has often relied on the 
multiplexing capability to analyze mixtures of compounds; however, this use is limited 
because most chemical libraries are formatted as arrays of individual compounds and 
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most screening is performed by testing one compound on one reaction at a time. MS is 
not commonly used for such screening because traditional sample introduction methods 
are too slow; although advances have been made with high flow rate separation and 
multiplexed autosamplers.
19,24
 As we describe here, a way to overcome this limitation is 
use of segmented flow sample introduction to enable label-free HTS by electrospray 
ionization (ESI)-MS.  
Segmented flow and other formats wherein aqueous sample droplets are 
compartmentalized within an oil carrier fluid have seen a resurgence of interest due to 
advances in microfluidic manipulation tools.
26,30,119-122
 Although most droplet 
experiments rely on optical detection, ESI-MS can also be used to analyze droplets.
38-
40,82,123-125
 Droplet sample introduction for MS allows fast analysis and greatly reduced 
sample consumption suggesting potential for HTS. So far experiments have focused on 
methods of interfacing droplets to MS on small scale demonstrations under conditions not 
compatible with HTS. A potential approach to HTS by droplet MS is to complete entire 
screening reactions at the droplet level yielding both label-free detection and 
miniaturization.
82
 However, a substantial infrastructure investment in MWP-based 
technology suggests that it is also of interest to combine such tools with MS, i.e. to 
develop a “MS plate reader”. Herein we describe coupling MWP-based fluid 
manipulation with segmented flow ESI-MS to rapidly screen a compound library. 
The system is applied to cathepsin B,
43
 a cysteine protease implicated in 
tumorigenesis, arthritis, and parasite infection.
47,51,126,127
 Both in vivo and in vitro studies 
have demonstrated that certain cathepsin B inhibitors reduce tumor cell motility and 
 54 
 
invasiveness.
50,128
 Because of these links, considerable effort has been made to identify 
cathepsin B inhibitors. Successful inhibitors include epoxysuccinyl, aziridinyl, biguanide, 
and -lactam derivatives.129,130 
Our approach to plate reading by MS is a two-step process of reformatting MWP 
samples into droplets and then infusion into an ESI-MS (Figure 3-1). We first examined 
the rate of ESI-MS analysis possible by this approach. For ESI, samples in a fluorinated 
ethylene propylene (FEP) tube are pumped into a metal-coated fused silica capillary that 
acts as the ESI needle (Figure 3-1B).
123
 The inner surface of the capillary is fluorinated 
so that it is wetted by the perfluorodecalin (PFD) carrier fluid. ESI voltage is applied 
continuously but electrospray stops and starts with each aqueous plug that exits the 
channel. The off-axis MS inlet prevents PFD, which is nebulized but does not form 
charged droplets, from entering the MS inlet (Figure 3-1B); thus a separation of oil and 
sample occurs in the gas phase.  
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Figure 3-1 A) Left: Scheme of parallel oil-segmented droplet generation from MWPs. 
FEP tubes are programmed to dwell in sample or oil for predetermined time, and then 
move to another well. The syringe pump operates in refill mode at a constant flow rate. 
Right: Picture of parallel droplets generation with different color food dye as samples. B) 
Diagram of ESI-MS analysis by direct infusion of segmented flow. Droplets are pumped 
into the ESI source through a treated ESI needle. ESI voltage is applied on the needle. In 
the gas phase, charged sample droplets (green) enter the MS and nebulized oil (yellow) 
does not. 
 
Experimental Section 
Chemicals and Materials. Unless otherwise specified, all solvents were 
purchased from Honeywell Burdick & Jackson (Muskegon, MI) and were certified ACS 
grade or better. Reagents were purchased from Sigma Aldrich (St. Louis, MO). Peptides 
used for cathepsin B assay were synthesized by Pierce Biotechnology, Inc. (Rockford, 
IL). Compounds for cathepsin B screening were from Prestwick Chemical Library® 
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(Prestwick Chemical, Washington, DC), provided by the Center of Chemical Genomics 
of University of Michigan. 
Parallel Droplet Generation. Oil-segmented droplets of 50 nL each were created 
in parallel from eight 384-well plates into eight 0.01 inch i.d. × 1/16 inch o.d. fluorinated 
ethylene propylene (FEP) tubes (IDEX Health and Science, Oak, Harbor, WA). A 2 cm 
100 m i.d. × 238 m o.d. fused-silica capillary, sealed with Sticky Wax (KerrLab, 
Orange, CA), was inserted into the inlet of each FEP tube to act as a “sipper”. Capillaries 
were fluorinated by pumping 1:100 (v/v) trichloro(1H,1H,2H,2H-perfluorooctyl) silane 
in anhydrous hexadecane through them. Samples in 384-well plates (Nunc™ 384-Well 
ShallowWell plates, Thermo Scientific) were covered with perfluorodecalin (PFD, 95% 
purity, Acros Organics, NJ). The edges of plates were built-up to 5 mm height with epoxy 
to hold PFD over the wells (Figure 3-1A).  
For droplet formation, the 384-well plates and the inlets of the FEP tubes were 
mounted onto a computer numerical control (CNC) machine (Cameron Micro Drill Press, 
Sonora, CA) so that a sipper was above the first well on each plate. The other end of FEP 
tubes were connected to 500 L Hamilton syringes (Fisher Scientific, Pittsburgh, PA), 
which were mounted on a multi-channel syringe pump (Fusion 400, Chemyx Inc. 
Stafford, TX). The syringes and FEP tubes were pre-filled with PFD. As the syringes 
were aspirating at 4 L/min, the G-code programmed CNC machine controlled the 
movement of tubes and plates so that the sipper could alternatively dwell in sample for 1 
s and in oil for 0.25 s, as well as move from sample to sample for 0.5 s. Droplets with 50 
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nL volume separated by equal size of oil were produced with these parameters (Figure 3-
2). 
 
Figure 3-2 Droplets of food dye solution generated in 8 FEP tubes at 4.5 Hz. The RSD of 
droplets within each tube is <5% and across tubes <10%. Photos show close-up view of 8 
tubes at different lengths along the tube. 
 
Mass Spectrometry Analysis. A Micromass Quattro Ultima triple quadrupole 
MS (Waters Corporation, Milford, MA) was used for analysis. The original stainless steel 
ESI needle was replaced by a piece of fused silica capillary  (18 cm in length, 100 m i.d. 
× 238 m o.d.) coated on the outside with gold and with the inner surface fluorinated as 
described above for sipper capillaries. The FEP tube containing sample droplets was 
connected to the treated ESI needle with a 1/16 inch bore VICI Cheminert union (Valco 
Instruments Co. Inc. Houston, TX).  
For analysis, a syringe pump drove sample droplets through the needle into the 
source. ESI voltage was +2.5 to 3.0 kV, the source was heated to 100 
o
C, the cone gas 
was set at 50 L/h, the desolvation gas was 200 L/h, and the nebulizing gas was adjusted 
to the best flow based on the infusing rate of droplets. The ESI mode and the MS method 
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were dependent upon molecules to be analyzed. Extracted ion currents (XICs) of target 
molecules were obtained by MassLynx (Version 4.1, Waters Inc.). Sample droplets are 
detected as bursts of current in the XICs because the oil, being not conductive or charged, 
does not generate ESI-MS signal. 
Cathepsin B Assay Development. The assay was developed from a previous 
report.
82
 The non-fluorogenic peptide GFGFVGG was used as substrate for cathepsin 
(Figure 3-3A). Reactions were performed in 20 mM ammonium formate and 200 M 
1,3-dithioerythritol (DTE) buffer. The buffer is MS compatible which allows direct 
infusion analysis (Figure 3-3B). Reactions were stopped with equal volume of the 
quenchant consisting of ice-cold 50% methanol, 50% water and 0.3% formic acid (v/v). 
The quenchant also contained 20 M of stable isotope labeled product (FVG*G, +3 Da) 
as internal standard. Calibration curves for detection of product peptide (FVGG), 
measured as a ratio to the internal standard, were linear from 0 to 500 M in this solvent 
as shown in Figure 3-3C. The rate of product formation was linear for 60 min when 
using 50 nM cathepsin B and 80 M substrate (Figure 3-3D). Michaelis-Menten analysis 
yielded a Km of 90.6 M (Figure 3-3E). Based on the kinetic studies, each screening 
reaction contained a final concentration of 80 M substrate and 50 nM cathepsin B, and 
was incubated for 25 min.  
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Figure 3-3. A) Assay reaction is cleavage of heptapeptide substrate GFGFVGG by 
cathepsin B; B) Full scan mass spectrum of direct infusion of the reaction mixture; C) 
Linear calibration of FVGG from 0 to 500 M; D) Reaction progression in 60 min with 
100 M GFGFVGG and 50 nM cathepsin B; E) Michaelis-Menten data of the reaction 
(Km > 200 M).  
 
Assay conditions were validated with a 24-compound pilot screen including 4 
known inhibitors: E-64, leupeptin, antipain and chymostatin at 25 M each. Dose 
response curves of those 4 inhibitors were also obtained under the same conditions 
(Figure 3-4). 
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Figure 3-4. Data from validation of assay conditions. A) 20 test compounds (No. 5-24) 
and 4 negative controls (No. 1-4) were used. Compound 5, 6, 7, 8 are known cathepsin B 
inhibitors: chymostatin, antipain, leupeptin and E-64, respectively. The rest are non-
inhibitors. B) Dose response curves of the 4 known inhibitors. Fitted IC50 values are 8.3 ± 
0.5 nM for E-64, 24 ± 8 nM for leupeptin, 41 ± 6 nM for antipain and 0.40 ± 0.04 M (n 
= 3) for chymostatin, which generally agree with the published values: E-64 = 55 nM, 
leupeptin = 21.5 nM,
130
 antipain = 0.48 M and chymostatin = 1.8 M.131 
 
High Throughput Cathepsin B Inhibitor Screening. To screen the Prestwick 
Library, 8 L of 100 M of GFGFVGG was deposited into each well of four 384-well 
standard assay plates (Greiner Bio-one, Monroe, NC) by Multidrop Combi (Thermo 
Scientific, Waltham, MA). 50 nL of 5 mM test compounds from the Prestwick Library 
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(1280 chemicals) was then added with a Caliper Life Sciences Sciclone ALH 3000 
Workstation (PerkinElmer, Waltham, MA). 2 L of 0.25 M cathepsin B was deposited 
into the mixture afterwards. The final concentrations were 80 M GFGFVGG, 50 nM 
cathepsin B, and 25 M test compound. 0.5% DMSO was present in each reaction. After 
incubation at 37 
o
C for 25 min, reactions were quenched with 10 L of ice-cold 
quenchant. In total 1408 reactions, including 64 negative controls (DMSO) and 64 
positive controls (25 M E-64) were performed. Assay plates were then spun to remove 
air bubbles. All mixtures were finally transferred into 384-well readout plates with 
elevated edges (see above) by Biomek Fx
p
 Laboratry Automation Workstation (Beckman 
Coulter, Brea, CA). Samples were reformatted to droplets as described above. Each 
sample was collected as 3 droplets in sequence. Four FEP tubes of 1 m length were used 
for each plate. Droplet and oil gap had equal volume of 75 nL. The analysis was 
performed using ESI-MS in multiple reaction monitoring with m/z transition 379.5 
247.1 for FVGG and 382.5247.1 for FVG*G. The collision energy was set as 18 eV, 
dwell time was 0.01 s and inter-channel delay was 0.01 s for both transitions. The ESI 
voltage was +2.7 kV. Droplets in FEP tubes were pumped into the sample cone at 15 
L/min. Droplet traces were acquired by MassLynx and processed with Origin 8.5.  
Hits Validation. Inhibitor hits were tested by dose dependent experiments, which 
were performed under the same condition as the screening. Each reaction contained a test 
compound from 0.1 M to 100 M (unless shown otherwise on the data plots). Peak 
height ratio of the product FVGG and the isotopic standard FVG*G were used for 
analysis. The data were normalized to a control reaction which contained no inhibitor. 
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Such normalization accounted for variation in reaction yield seen from day to day, 
possibly due to enzyme variation during storage. IC50 values were obtained from dose 
response curves, which were fitted by GraphPad Prism 6.01. 
Fluorescent Assays. Six of the inhibitor hits were re-tested by fluorescent assays. 
20 M of fluorogenic substrate Z-Arg-Arg-7-amido-4-methylcoumarin hydrochloride 
(ZRR-AMC, Sigma Aldrich), 50 nM cathepsin B and 0.1 M to 100 M (or wider range) 
test compound were used. Reaction conditions were the same as MS-based dose 
dependent experiments. The results were readout by Packard Fusion Microplate Reader 
(PerkinElmer) with excitation wavelength at 348 nm and emission wavelength at 440 nm. 
The comparison with MS assay is shown in Figure 3-11.  
 
Results and Discussion 
Mass spectra obtained for segmented samples are comparable to direct infusion. 
We do not detect signals that can be attributed to PFD at any time during infusion of 
samples (Figure 3-5), which suggests effective separation and no detrimental effects of 
oil on the MS performance. 
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Figure 3-5 Demonstration that oil does not affect the analysis of target molecules: A) left: 
averaged mass spectra of direct infusing FVGG (m/z 379) and FVG*G (m/z 382) in 
continuous flow (top) and in segmented flow (bottom); right: oil segments in 107 y-axis 
scale (top) and same oil segments in 105 y-axis scale (bottom); B) averaged mass spectra 
of perfluorodecalin at different periods of time. The signal intensity of the oil is low. The 
absence of consistent peaks indicates that the oil is not ionized in the source and does not 
interfere with the analysis of any other compound. 
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The rate of mass spectra acquisition sets the ultimate limit for analysis rate. The 
highest scan rate of the MS used for this work is 62 scans/s for single ion monitoring and 
27 scans/s for two ions. For quantitative analysis, it was desirable to obtain 6-8 scans per 
droplet which means that the analysis rate can be up to 5 Hz (i.e., 5 samples/s) for 
measuring a single ion and 2 Hz for two ions (assuming a 1:1 ratio of sample:oil). For 50 
nL droplets, the MS-limited rate of 5 Hz could be achieved with an infusion flow rate of 
30 L/min. This rate produced stable traces and reproducible detection of a select ion 
showing that the ESI can stop and start at such rates (Figure 3-6). We could reliably 
infuse up to 500 droplets at a time, the largest read length tested.  
    
Figure 3-6 Top: Traces of 384 droplets containing 5 M adenosine (solvent: 20% 
methanol, 0.1% formic acid) analyzed in 1.3 min (5 Hz). Droplets are 50 nL each and the 
infusion rate is 30 L/min. Bottom: the zoom-in view of 0.2-0.4 min. The RSD of droplet 
signal is ~5%. Droplets are segmented by oil plugs which are not charged thus do not 
yield signal. MS method: single reaction monitoring (SRM), m/z 268136. Each 
droplet-oil pair consists of 10 to 12 data points. 
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Analysis rate is also affected by the amount of carry-over that can be tolerated 
because we found a link between carry-over in the mass spectrometry signals and 
analysis rate. For example, for 5 M adenosine followed by a blank droplet we detected 
no carry-over at 1 sample/s; but 10% at 2 samples/s and 20-30% at 4 samples/s (Figure 
3-7). We observed no cross-contamination between droplets within the storage tubes, 
presumably due to low partition coefficients into the carrier fluid and wetting of the FEP 
surface by PFD. Therefore, the carry-over may be due to cross-droplet contamination 
occurring during transfer from FEP to ESI needle, within the needle, or in the gas phase. 
With the present system, carry-over can be reduced by decreasing the analysis rate or by 
introducing replicate samples. In the latter case, contamination becomes negligible in 
subsequent droplets so that averaging the signal from 3 droplets gives good quantification. 
Use of triplicate samples also provides redundancy for cases where a noise spike affects a 
measurement.  
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Figure 3-7 Carry-over evaluation at different analysis rate. 5 M adenosine and solvent 
(20% methanol, 0.1% formic acid) alternating droplets (5 each) were infused into the ESI 
source for analysis. At 0.9 Hz, the carry-over is almost zero; at 1.8 Hz, it increases to 
10%; at 3.6 Hz, it becomes as high as 20~30%. Red arrows indicate blank droplet that 
contains signal due to carry-over. 
 
It is necessary to have rapid reformatting from MWP to droplets for overall high 
throughput. Previous reports demonstrated up to 0.15 droplets/s for forming segmented 
arrays from MWP which would be rate limiting in this case;
132
 therefore, we explored 
increasing the rate of this step. Reformatting followed the general procedure previously 
described for PCR in droplets.
133
 In this method, samples in a MWP are covered with a 
continuous layer of oil. The tip of a FEP tube, connected at the opposite end to a syringe 
operated in withdraw mode, is moved from well-to-well to generate samples separated by 
oil segments. Fast movement and high aspiration rate contribute to high droplet 
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generation rate. Using an aspiration rate of 4 L/min allowed at least 400 droplets of 50 
nL to be formed inside a 90 cm long tube at a rate of 0.58 Hz and a droplet size relative 
standard deviation (RSD) <5% (Figure 3-2). Higher aspiration rate tended to produce 
progressively smaller droplets as the tube was filled, likely due to increased leaking as 
the flow resistance increased with more droplets. To prevent droplet generation from 
being rate limiting, tubes can be operated in parallel. For example, we operated 8 tubes 
simultaneously to give an overall sample generation rate of 4.5 Hz with an RSD of 
droplet size across tubes <10% (Figure 3-2).  
We used this system to screen the Prestwick Chemical Library, consisting of 
1,280 FDA-approved drugs, against cathepsin B. The assay used the  heptapeptide 
GFGFVGG, a sequence representing the proteolytic preference of cathepsin B, as 
substrate.
111
 Although we have previously demonstrated an MS assay for cathepsin B,
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we modified reaction conditions for screening to use substrate concentration (80 M) 
below the Km and an incubation time that ensured linear reaction velocity. During the 
screen, the product peptide (FVGG) and a stable isotope-labeled form of this peptide 
(FVG*G), added after the reaction was complete, were detected. Although adding 
detection of isotope-labeled standard required a slower MS scan rate, it was necessary to 
correct ion suppression and signal drift. The screen used standard MWP fluid 
manipulation for creating the reaction mixtures in 384-well plates and therefore can be 
incorporated into existing MWP screening systems. 
Performing the assay, including reagent dispensing, incubation, and transferring 
to detection plates, took 1 h. The 1,408 reaction mixtures (1,280 test compounds and 128 
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controls) were reformatted into 4,224 droplets of 70 + 7 nL. Droplets were generated at 
0.5 Hz/tube and MS analysis was conducted continuously at 1.6 Hz (Figure 3-8). The 
analysis of all sample droplets took ~45 min. Carry-over was lower than 15% from 
droplet to droplet during the screen, which did not affect the analysis of triplicate samples 
(Figure 3-9). The assay was robust as the Z-factors of all plates were above 0.72.  
 
Figure 3-8 A) Top: droplet traces of partial cathepsin B inhibitor screening (Plate #4, 320 
test compounds, 16 negative controls (-), and 16 positive controls (+)). Each reaction is 
analyzed in triplicate. The analysis rate is 1.6 Hz (1056 droplets detected in 670 s. 
Bottom: The enlarged view of 550-670 s. Inhibitors (blue arrows) are identified by the 
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low intensity ratio of FVGG/FVG*G. B) Top: the analysis result of Plate #4. Each bar is 
the averaged FVGG/FVG*G of an assay. The negative control is normalized to 100% 
activity. Bottom: the last 135 reactions and controls (green). Inhibitors (red) are identified 
by the low % of activity (n = 3). 
 
 
Figure 3-9. A) Sample droplet traces for portion of cathepsin B inhibitor screening (Plate 
#3, 320 test drugs, 16 negative controls (-), and 16 positive controls (+)). The analysis 
rate is 1.6 droplets/s; B) Zoom-in view shows the transition from negative control to 
positive control. The carry-over (red arrow) is only 12.5% for the first positive control. 
For the first 3 positive controls, the carry-over only affects the signal by 4.8%. 
 
Among 1,280 test compounds, 9 reduced the reaction yield more than 50% and 15 
inhibited the reaction ~40%. Interestingly, all hits were confirmed by dose response 
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assays (Figure 3-10), showing a low false positive rate (See Appendix B for goodness of 
fit of the sigmoidal model, and Appendix C for the structures of all hits).  
Of the 24 chemicals that reduced the reaction yield 40% or more, 4 were known 
cathepsin or cysteine proteases inhibitors (chlorhexidine, luteolin, ethacrynic acid, and 
disulfiram). Another 6 hits (triclabendazole, hexachlorophene, anthralin, raloxifene, 
triclosan, and diacerein) have not been reported as cathepsin inhibitors, but are used to 
treat diseases in which cathepsins play a role. For example, triclabendazole is used to 
treat liver flukes which secrete cathepsins.
134,135
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Figure 3-10. Dose response curves of the identified inhibitors. A) inhibitor hits that 
found to be related to cathepsins (chlorexidin,
136
 luteolin,
137
 triclabendazole,
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ethacrynic acid,
138
 disulfiram,
139
 hexachlorophene (also strong inhibitor),
140,141
 
anthralin,
142
 raloxifene,
143
 triclosan,
144-146
 and diacerein (strong inhibitor)
147,148
); B) drug 
molecules that reduced the yield by more than 50% in the primary screen but had no prior 
link to cathepsins (cefmetazole, zafirlukast, thioguanosine, didanosine, alexidine, 
avobenzone, and tegaserod); and C) those reduced the yield by ~40% in the primary 
screen but had no previous link to cathepsins (cefaclor, colistin, pinaverium, metergolin, 
diethylstilbestrol, butenafine and pimozide). Error bars are for 3 replicates. 
 
The cathepsin inhibitory effect of the other 14 hits has yet to be studied, which 
suggests potential new therapeutic use for these compounds. Among them, 3 contain 
known „warheads‟ of small molecule cathepsin B inhibitors (cefmetazole and cefaclor are 
-lactams and alexidine contains a biguanide130). The remaining 11 hits do not contain 
structures established as cathepsin B inhibitors, suggesting an opportunity to develop 
modulators based on novel moieties. 
To further validate the results, we performed fluorescent assays on several of 
these hits to test results in an orthogonal assay (Figure 3-11). The tested compounds all 
yielded dose response curves in both assays with similar IC50 values. Variation may be 
attributed at least in part to use of different substrates for the assays. 
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Figure 3-11. Comparison of dose response curves of 6 hits from fluorescent assay with 
MS assay. Fitted IC50 values generally agree with each other. 
 
In principle, this system can achieve high throughput for a large number of 
samples. For example, 3,072 droplets can be created from eight 384-well plates within 12 
min and analyzed in 26 min. Switching tubes from aspiration to MS manually required 4 
min for 8 tubes. By overlapping droplet generation of the new batch with the analysis of 
the previous one, 147,456 droplets could be analyzed in 24 h suggesting the potential for 
ultra-high throughput MS analysis (Figure 3-12). The switching of tubes could be 
automated for faster analysis. Improving the read length could also reduce the number of 
times that this step is required further improving throughput. Another improvement may 
be integrating high throughput sample preparation prior to the reformatting. Utilizing 
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parallel desalting multi-well plates could extend the applicability of the system to the 
assays that strictly require non-volatile buffers or additives.  
 
Figure 3-12 Timing diagram for batch mode operation using mass spectrometry plate 
reader. Reformatting samples from MWPs into 3,072 droplets takes 12 min (4.5 Hz); MS 
analysis takes 30 min (2 Hz, plus the tubing switching time). By overlapping the 
reformatting and analysis of continuous batches, 147,456 droplets could be analyzed in a 
day. 
 
Conclusion 
These results demonstrate that droplet ESI-MS has the robustness and throughput 
to be used for HTS applications. The system provided reliable results for over 4,000 
samples in a HTS workflow. The low false positives and identification of novel 
compounds support the idea that high-throughput, droplet-based ESI-MS can be a 
powerful tool for label-free screening. Although the current droplet system has higher 
throughput than systems which use solid-phase extraction or LC,
149,150
 it is restricted to 
assays that can be performed in ESI-MS compatible buffers. Although many targets will 
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likely be compatible with such buffers, this limitation does suggest that future work 
should be directed towards methods of rapid sample clean-up, e.g. parallel solid phase 
micro-extraction
151
 or in-plate solid-phase extraction
152,153
 so that so the high throughput 
capability could be used with a wider range of assays. Another important advantage 
relative to current MS-based methods is that this approach uses miniscule fractions of a 
sample and therefore could be compatible with lower volume, higher-density well plates 
for reduction of reagent consumption. Overall, these results suggest that the droplet based 
method adds to or complements existing MS screening systems.  
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CHAPTER 4 
DEVELOPMENT OF LABEL-FREE SIRTUIN 1 ASSAY FOR HIGH 
THROUGHPUT MODULATOR SCREENING USING SEGMENTED FLOW-
ELECTROSPRAY IONIZATION MASS SPECTROMETRY 
 
Introduction 
High throughput screening (HTS) is a technology that can rapidly identify 
biological active compounds against a panel of targets through millions of assays. 
Though HTS is dominated by optical detection methods, especially fluorescence plate 
readers, label-free analyses have gained increasing attention in recent years.
1,2
 Performing 
assays without incorporating artificial labels are beneficial in several ways: minimal 
manipulation on the reaction components, less assay artifacts such as auto-fluorescence 
from test compounds, relatively simplified assay development, and lower reagent cost for 
large-scale screenings.
6,7
  
One of the most powerful label-free analyzers is mass spectrometry (MS). The 
capability of identifying analytes solely based on mass to charge ratio, and features of 
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high sensitivity, rapid scanning and multiplexing make MS a promising detector for high 
throughput screening (HTS).
7,24,102,116
 The potential high analysis rate of MS is often 
compromised by slow sample introduction approaches or the requirement of sample 
preparation. It inspired us to seek for alternatives. Droplet microfluidics is an attractive 
platform for HTS because it can reliably manipulate nanoliter scale samples and conduct 
miniaturized reactions with high speed, precision and automation.
26
 Previous works have 
shown that oil-segmented droplets can be directly infused into electrospray ionization 
(ESI) source for rapid analysis of discrete samples with minimal carry-over.
40,82,123
 
Screenings for enzyme modulators have been carried out using droplets-ESI-MS 
system.
41,82,83
  
Sirtuins are a class of conserved NAD
+
-dependent deacetylases. There are seven 
mammalian homologues identified: SIRT1 to SIRT7. The activities of sirtuins influence 
DNA repair, gene silencing, cellular stress resistance, tumorigenesis, energy metabolism 
and longevity. The relation between sirtuins and aging-related diseases has attracted most 
attention.
56
 Mammalian SIRT1 is evolutionarily closest to the founding member of sirtuin 
family, yeast Sir2. It is localized in nucleus, but can be shuttled to the cytoplasm in need, 
dependent on the tissue.
154
 The function of SIRT1 encompasses a wide spectrum. It 
improves genomic stability by deacetylating various factors related to DNA repair; 
protects cells against stress by regulating the heat shock response; interacts with p53 to 
modulate the threshold for cell death in response to stress; deacetylates PGC-1 which is 
a transcriptional coactivator regulating hepatic gluconeogenesis and fatty acid oxidation; 
elevates the secretion of insulin under stimulation of glucose; affects vascular biology 
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through influence several factors; and counteracts inflammation in age-related diseases 
by negatively regulates NF-B.154-156 Due to the increasing evidence that SIRT1 may 
mitigate metabolic dysfunctions, researchers have never ceased the effort in searching for 
its activators. Several SIRT1 activators have been discovered by a fluorogenic assay. In 
vivo studies confirmed their beneficial effects in metabolism. However, due to the 
involvement of the fluorescent label, whether they directly impact SIRT1 remains 
disputable.
60
 
In this work, we seek to develop a label-free SIRT1 assay which can be analyzed 
by droplet-ESI-MS system without sample preparation. SIRT1 was first dialyzed into an 
ESI-compatible formate buffer prior to the screening. Reactions were then conducted in 
the formate buffer, instead of the commonly used Tris buffer. Afterwards, samples in a 
multi-well plate were reformatted into oil-segmented nanoliter droplets and finally 
infused into ESI-MS for analysis (Figure 4-1). The assay was tested by a pilot screen 
involving 80 test compounds with known properties. Inhibitor hits were validated by dose 
response experiments. The system is applicable to any scale SIRT1 modulator screening 
and is possible to be generalized to other enzymes. 
 
 79 
 
 
Figure 4-1 Diagram of SIRT1 assay: SIRT1 was dialyzed from Tris buffer into formate 
buffer using a centrifugal dialysis unit; then the deacetylation reactions were conducted in 
formate buffer in a multi-well plate; reaction mixtures were afterwards reformatted into 
oil-segmented droplets in a piece of FEP (fluorinated ethylene propylene) tube; finally, 
droplets were infused into an orthogonal ESI source through a modified ESI needle. The 
FEP tube and the needle were connected by a ZDV (zero dead volume) union. The signal 
intensity of the reaction product and its isotopic internal standard are monitored. Oil 
segment did not generate any ESI signal thus showed as spacing between sample droplets. 
 
Experimental Section 
Chemicals and Materials. Unless otherwise specified, all solvents were 
purchased from Honeywell Burdick & Jackson (Muskegon, MI) and were certified ACS 
grade or better. Reagents were purchased from Sigma Aldrich (St. Louis, MO). Human 
recombinant SIRT1 and Epigenetic Screening Library were purchased from Cayman 
Chemical (Ann Arbor, MI). Histone H3K9(Ac) and H3K9 were purchased from AnaSpec 
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(Fremont, CA). Isotope labeled H3K9 was synthesized by the Marsh lab, University of 
Michigan. 
MS-based SIRT1 Assay. The original buffer of SIRT1 (50 mM Tris-HCl and 
140 mM total inorganic salts, pH 8.0) was exchanged into an ESI-MS-compatible buffer 
(200 mM ammonium formate, 200 M dithiothreitol (DTT) and 200 M NAD+, pH was 
adjusted to 8.0 by ammonium hydroxide) using Amicon Ultra-0.5 mL (EMD Millipore, 
Billerica, MA) with 50 kD cutoff. Each 50 L SIRT1 (1 mg/mL) was dialyzed against 
500 L formate buffer twice. The collected SIRT1 was diluted by the new buffer to the 
designated concentration. The procedure was conducted at 4
o
C.  
An unlabeled 21-mer peptide H3K9(Ac) (ARTKQTARK(Ac)STGGKAPRKQLA) 
was selected to be the substrate. The deacetylation product is H3K9 
(ARTKQTARKSTGGKAPRKQLA) (Figure 4-2). Reactions were performed in the 
formate buffer and terminated with equal volume of quenching reagents consisting of 50% 
methanol, 50% water, 0.2% formic acid (v/v) and 10 M isotope-labeled H3K9 (H3K9*, 
+12 Da).  
The linearity of the reaction was assessed by a series of assays incubated for 0, 15, 
30, 60, 90, 120 min. Each assay contained final concentration of 0.5 M SIRT1 and 20 
M H3K9(Ac). The Michaelis−Menten kinetics were measured by varying H3K9(Ac) 
concentration from 0 to 160 M and quenching the reaction at different times from 0 to 
120 min. The Km value was fit by Michaelis-Menten model with GraphPad Prism 6.01. 
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The detection of product H3K9 was calibrated by measuring the intensity ratio of H3K9 
over H3K9*. The curve was linear from 0 to 25M H3K9 (Figure 4-4).  
Epigenetic Library Screening. The screening was performed in part of a 384-
well plate (Greiner Bio-one, Monroe, NC), in 8 × 13 format. Screening conditions were 
determined by the assay development. 50 L SIRT1 at 11 M was buffer exchanged and 
then diluted to 650 L by the formate buffer. Column 1, 6 and 13 were added with 1 L 
10% DMSO as negative control. Column 2-5 and 7-12 were added with 1 L test 
compound at 200 M in 10% DMSO from the Epigenetic Screening Library. 6 L of 
new SIRT1 solution was then added to each well by Matrix Electronic Multichannel 
Pipette (Thermo Scientific, Waltham, MA). Afterwards, 3 L of 67 M H3K9(Ac) was 
deposited into each well. The final concentrations were 20 M test compounds, 0.5 M 
SIRT1, and 20 M H3K9(Ac). Each reaction contained 1% DMSO. Reactions were 
incubated at 37
o
C for 1.5 hours and then quenched with 10 L ice-cold quenching 
reagent. 
Droplet-MS Analysis. Reaction mixtures were first transferred into a custom 
384-well readout plate,
83
 and then reformatted from the readout plates into oil-segmented 
droplets which were stored in a piece of fluorinated ethylene propylene (FEP) tube. The 
oil phase was perfluorodecalin (PFD). The procedure has been previously described.
83
 
Each reaction was collected as 3 droplets of 100 nL each. The oil gap was the same size 
with the droplet.  
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The MS analysis was performed by Micromass Quattro Ultima triple quadrupole 
MS (Waters Corporation, Milford, MA) in full scan mode (m/z 550-785). The scan time 
was set as 0.05 s. The ESI voltage was +3.0 kV. Droplets were pumped into the source 
through a custom ESI needle at 10 L/min.123 Droplet traces were acquired by MassLynx 
4.0. The intensity of [M+3H]
3+
 (m/z 752.6) and [M+4H]
4+ 
(m/z 564.6) ions of the product 
H3K9 and isotopic standard H3K9* (m/z 756.3 and 567.4) were measured for 
quantifying the reaction yield (Figure 4-2). Data was analyzed by Origin 8.5. 
Dose dependent experiment. Compounds that reduced the reaction yield by 
more than 50% were selected as strong inhibitor hits. A series of reactions containing a 
concentration range of the hits (as indicated in Figure 4-6) were performed. Each 
reaction contained final concentration of 0.5 M SIRT1 and 20 M H3K9(Ac). After 
incubation at 37
o
C for 1 hour, reactions were stopped by ice-cold quenching reagents 
which had 20 M H3K9* in it. The dose response curves were fitted using GraphPad 
Prism 6.01. 
 
Results and Discussion 
MS analysis. H3K9 and H3K9* are multiply charged in the full scan mass 
spectrum (Figure 4-2). Charge states from [M+7H]
7+
 to [M+3H]
3+ 
are observable on the 
spectrum. However, scanning a wide mass range reduces the analysis rate. We found that 
the [M+4H]
4+ 
and the [M+3H]
3+ 
peaks dominate the mass spectrum and the sum of their 
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intensity can be linearly calibrated with peptide concentration. Therefore we narrowed 
down the scan range to m/z 550-785. The scan time was set as 0.05 s to ensure adequate 
ion abundance. 
 
Figure 4-2. Deacetylation of H3K9(Ac) by SIRT1. The reaction is shown on the top. The 
lower mass spectra show a reaction without any modulator (negative control) and a 
reaction with an inhibitor. Triply charged and quadruply charged H3K9 (red arrows), 
H3K9* (black arrows) and H3K9(Ac) (blue arrows) are monitored. Intensity ratio of 
H3K9/ H3K9* is calculated for quantification. 
 
Buffer Exchange for SIRT1. Many components in buffers for enzymatic 
reactions may affect the ESI process. Millimolar level non-volatile salts, such as NaCl 
and K2HPO4 severely suppress the signal of other compounds. Some other components, 
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such as Tris or glycerol compete for the charge on the surface of the ESI droplets with the 
target analytes, especially when these components are very concentrated. In order to 
make the SIRT1 reaction directly analyzable by ESI-MS, we have developed a reaction 
buffer containing volatile salt ammonium formate and a small molecule reducing agent 
DTT which would not affect the ESI process of any other compounds.  
A spin dialysis unit was chosen for buffer exchange due to its high speed and 
efficiency. The dialysis was performed at 4
o
C to prevent heating of the protein during 
centrifugation. We found that one spinning unit can dialyze 50 L of SIRT1 (~50 g) 
with best desalting effect and recovery. For complete removal of salts and other 
interferences, 1000 L of formate buffer was used, 500 L each time. We explored 
several combinations of centrifugal force and centrifuging time and found that using 8000 
g and 4 min/spin, SIRT1 could be completely desalted, and its deacetylation activity was 
maintained to the largest extent.  
Ammonium Buffer for SIRT1 Assay. We compared the deacetylation activity of 
SIRT1 before and after buffer exchange. The reaction yield was nearly 100% after 4 hour 
incubation in the original Tris buffer and about 90% in the formate buffer (See 
chromatograms in Figure 4-3). It proves that the desalting process does not adversely 
affect the activity of the enzyme, and the reaction runs efficiently in the formate buffer. 
We believe that Tris is not essential to this protein for both the structure and catalytic 
ability. Other enzymes which are not strict on the buffer might also react under such 
condition, which allows direct ESI-MS analysis. 
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Figure 4-3. Left: reaction conducted in the Tris buffer. Observed from TIC (total ion 
current), nearly 100% yield was achieved. Right: reaction conducted in the formate buffer. 
A little substrate was not converted. But the yield was still high enough which indicates 
good enzyme activity. (Column: made-in-house 8 cm fused- silica capillary column (75 
m i.d./360 m o.d.) packed with 5 m C18 particle.157 Mobile phase A: 0.15% formic 
acid aqueous solution. Mobile phase B: methanol. Linear gradient: initial, 0% B; 10 min, 
50% B; 15 min, 50% B; 18 min, 95% B; 20 min, 100% B). 
 
Assay Condition Optimization. We chose a known SIRT1 substrate: H3K9(Ac) 
(Ac-Histone H3 lysine 9) as the assay substrate. Because it is not labeled, it avoids any 
possible interference, and it can only be analyzed by MS. To better mimic deacetylation 
of histone H3 protein by SIRT1, we chose a peptide consisting of 21 amino acids. 
Smaller peptides might not interact with the SIRT1 catalytic site in the similar way with 
the whole protein, while larger peptides will challenge the analysis rate, sensitivity and 
quantification of MS. 
It is necessary to study the kinetics of an enzyme before screening for modulators. 
Competitive or reversible modulators are of most interest because they are usually less 
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toxic than irreversible ones. Performing the assay under its initial velocity conditions 
increases the sensitivity to the desired modulators. The concentration of the substrate 
needs to be under or equal its Km value so that it will not saturate the catalytic site of the 
protein. The reaction time should be limited to when the product is still accumulating 
linearly. By that time the substrate has not been largely converted into product and the 
reverse reaction does not significantly affect the turnover rate.
1
 Searching for activators 
require more critical conditions. It is crucial to keep the substrate concentration low so 
that the reaction rate can be elevated by activators. 
We studied SIRT1 kinetics by conducting a set of assays starting with different 
substrate concentrations and were quenched at a range of times. We found that the Km 
value of H3K9(Ac) is 22 M (published Km is ~ 40 M
71
). For 0.5 M SIRT1, reaction 
yield grows linearly for up to 2 hours when H3K9(Ac) is 20 M (Figure 4-4A, B). 
Therefore, we decided to use 20 M H3K9(Ac) and 1.5 h incubation for the screening. 
Linear response for the target analyte is crucial. In the SIRT1 assay, we monitored 
H3K9 and its isotopic internal standard. The intensity ratio of H3K9 over H3K9* 
increases linearly with H3K9 concentration up to 25 M (R2> 0.99) (Figure 4-4C). 
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Figure 4-4. A) Michaelis-Menten model of H3K9(Ac) with 0.5 M SIRT1. The fitted Km 
value is 22 M. B) Linear reaction within 2 h. C) Linear calibration curve of 0 to 25 M 
H3K9. Intensity ratio of H3K9 to H3K9* was measured (n = 3). 
 
Screening. The assay conditions were tested by a pilot screening against the 
Epigenetic Screening Library, which is made up of 80 epigenetic modulators, including 
known SIRT1 inhibitors. Another 24 reactions only containing 1% DMSO were 
performed as the negative control. The controls were placed at the beginning, in the 
middle, and at the end of the screening. To avoid precipitation or aggregation effect, test 
compounds are typically in 10-30 M range. Also, low concentration can rule out weak 
modulators. For our screening, each test compound was 20 M. The concentration of 
H3K9(Ac) and the incubation time were determined based on the enzyme kinetic studies. 
Matrix multichannel pipette was utilized for rapid and reproducible reagents dispensing 
to make the start time of all reactions was as close as possible. The similar intensity ratio 
of H3K9 over H3K9* of all negative controls demonstrates the simultaneous reaction 
initiation (Figure 4-5A). Therefore, the yield in test reactions can be compared with the 
negative control. 
After transferring reactions from the assay plate into custom readout plate which 
was described before,
83
 104 reactions were made into triplicate droplets (312 droplets in 
total) at 0.5 Hz. Replicates are necessary because it provides backup data when signal 
spikes or occasional fluctuation affecting the detection. Besides, if the carryover affects 
the measurement, the first droplet of each sample set may not be analyzed.  
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Droplets were detected by MS in a full scan mode, yielding stable signals (Figure 
4-5A). The detection of all 312 droplets took ~5 min (0.8 Hz). The results are 
straightforward as a low H3K9/H3K9* suggests a potential inhibitor (Figure 4-6B, C). 
The assay was reliable as the Z-factor was 0.7. The isotopic internal standard is useful for 
correcting the impact of certain test compounds on the ESI process of the product peptide. 
In this 80-compound screening, we set the inhibitor criteria as reducing the yield 
by more than 50%. This standard might miss some weak SIRT1 inhibitors, but we aimed 
at identifying strong inhibitors. 4 compounds met the criteria: suramin, EX-527, C646 
and anacardic acid. Suramin and EX-527 are known SIRT1 inhibitors.
158-160
 Anacardic 
acid has recently been found to have potential to inhibit sirtuins.
161,162
 Inhibition by C646 
has not been reported yet. Their inhibitory potency was evaluated by dose response 
experiments (Figure 4-6). The fitted IC50 of EX-527 and suramin agree with the 
published values (EX-527: 100 nM;
159
 suramin: 300 nM
158
). Other known SIRT1 
inhibitors which were not identified in this screening might because their inhibition 
potency is relatively low. For example, the IC50 of nicotinamide is > 50 M,
163
 sirtinol is 
131 M,164 and Tenovin-6 inhibits 40% of SIRT1 activity at 20 M.165 Those compounds 
showed 22%, 30% and 30% inhibition at 20 M in my screening, respectively. 
The activator criterion is elevating the yield by more than 50%. In this screening, 
no activator was identified (Figure 4-5C). The Epigenetic Library includes resveratrol 
and piceatannol, both of which are allegedly SIRT1 activator (being reported to increase 
the turnover rate by at least 3 times
59,71
). However, the result of our MS assay as well as 
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other label-free assays
68,69
 do not confirm such activation effect. The real mechanism of 
these activators calls for further study. 
 
Figure 4-5. Epigenetic library screening: A) Raw droplet traces of the screening. The 
upper trace is the reaction product H3K9, the lower one is the isotope-labeled internal 
standard H3K9*. The first 3 sets are negative controls at the beginning, in the middle, and 
at the end of the assay plate, respectively. B) Enlarged view of the control, reaction 
containing suramin, and some other test reactions droplets. C) The final analysis of the 
screening. Each bar is the averaged H3K9/H3K9* of an assay. The negative control 
(green) is normalized to 100% enzyme activity. 4 reactions showed that the enzyme 
activity was lowered by more than 50% (n = 3). 
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Figure 4-7. Dose response curves of 4 inhibitor hits. The negative control of each 
experiments were normalized to 100% activity (n = 2). 
 
Conclusion 
We have developed a label-free SIRT1 assay which can be applied to droplet-ESI-
MS high throughput screening system. The screen against Epigenetic Screening Library 
involving 80 test compounds demonstrated the high throughput (0.8 Hz) and high 
reliability (Z-factor = 0.7) of the assay. The approach can be logically generalized to any 
enzyme that maintains good activity in the described MS-compatible condition. The wide 
applicability of ESI-MS makes possible the detection of a variety of reaction products. 
This method can be complementary to but faster and more economical than the solid 
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phase extraction (SPE)-ESI-MS screening method
19
. Future directions include applying 
the label-free SIRT1 assay to large scale SIRT1 modulator screening in search of 
molecules that directly interact with SIRT1. Other MS-compatible conditions can be 
explored to further improve the universality of this concept. 
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CHAPTER 5 
DEVELOPMENT OF MASS SPECTROMETRY-BASED ASSAYS FOR HIGH 
THROUGHPUT SIRTUIN 6 MODULATOR SCREENING 
 
Introduction 
Sirtuin 6 (SIRT6) is one of the 7 mammalian human sirtuins, which are a group of 
highly conserved NAD
+
-dependent deacetylases. SIRT6 is predominantly localized 
inside the nucleus and associated with the chromatin. SIRT6 mainly acts as adenosine 
diphosphate (ADP) ribosylase, histone deacetylase and deacylase. SIRT6-knockout mice 
suffer from increased genomic damage and instability, progeroid syndrome, 
hypoglycemia, and early death. A study showed that transgenic mice overexpressing 
SIRT6 have had lifespan enhanced by 15%. Though the effect was only observed in male 
mice, it suggests that SIRT6 might be central in controlling aging.
75
 SIRT6 protects 
telomeres on chromatin through deacetylating histone H3 lysine 9.
56
 SIRT6 removes 
ADP-ribose from PARP-1 that leads to DNA repair. Besides, SIRT6 regulates the 
transcription of hundreds of genes thus participates in many metabolic pathways.
154
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Because of the beneficial effect of SIRT6 overexpression, molecules that activate SIRT6 
are especially interested in treating aging-related metabolic diseases. To date, only a few 
SIRT6 modulators have been reported.
79,81,166
 Motivated by the success of our cathepsin 
B inhibitor screening, we plan to make our contribution to the search for SIRT6 
modulators by using the mass spectrometry plate reader.  
In this work, we developed 2 SIRT6 MS assays which are readily to be used in a 
large-scale screening. In the first assay, we strive to conduct the reaction in the SIRT6-
preferred environment. Deacetylation of H3K9(Ac) by SIRT6 was performed in the 
traditional Tris buffer. Reactions were diluted by 20 folds before reformatting into 
droplets. A test screening against 25 test compounds proved the high reliability of this 
method. We also evaluated the data quality of single detection compared with triplicated 
detection (making one droplet per reaction versus making three). Without replicates, the 
analysis rate was reduced from up to 2 Hz to 0.7 Hz to avoid carryover and high spikes 
which tend to occur in rapid analysis. But unlike triplicate detection, the actual 
throughput (samples/s) is not 1/3 of the droplet analysis rate (droplets/s). Therefore, 
single detection leads to slightly higher throughput than triplicate detection. Besides, less 
droplets are required to be generated for the whole screening.  
The second assay was developed with another substrate: decanoylated histone H3 
lysine 9 (H3K9(decanoyl)). SIRT6 has been shown to be very efficient in deacylation. 
Long chain fatty acylated proteins are potentially endogenous SIRT6 substrates.
78
 
Modulators discovered from this assay may have completely different physiological 
functions with the deacetylation assay. 
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Experimental Section 
Chemicals and Materials. Unless otherwise specified, all solvents were 
purchased from Honeywell Burdick & Jackson (Muskegon, MI) and were certified ACS 
grade or better. Human recombinant SIRT6 was purchased from Cayman Chemical (Ann 
Arbor, MI). Histone H3K9(Ac) and H3K9 were purchased from AnaSpec (Fremont, CA). 
Isotope labeled H3K9 was synthesized by the Marsh lab, University of Michigan. Histone 
H3K9(decanoyl) was synthesized by Pierce Biotechnology Inc. (Rockford, IL).  
Deacetylation of H3K9(Ac) by SIRT6. 3 M of human recombinant SIRT6 (1 
mg/mL in 50 mM Tris-HCl, 140 mM total inorganic salts, and 10% glycerol) and 60 M 
of H3K9(Ac) (NH2-ARTKQTARK(Ac)STGGKAPRKQLA-OH) were mixed into 
NAD
+
-Tris buffer (500 M NAD+, 50 mM Tris-HCl and 200 M DTT, pH was adjusted 
to 7.5 by ammonium hydroxide). 100 M oleic acid or different concentrations of DMSO 
was added as needed. After incubation at 37
o
C for 4.5 hours, the reactions were quenched 
by 19-time volume of ice-cold quenchant (30% MeOH, 70% H2O, 0.1% formic acid 
(v/v)), and 0.5 M isotope-labeled internal standard H3K9* (+12 Da)).  
Mass Spectrometry Analysis. The quenched and diluted reaction mixture was 
infused into a triple quadrupole mass spectrometer (Micromass Quattro Ultima, Waters 
Corporation, Milford, MA). The MS parameters were set as follows: capillary voltage 2.5 
kV, cone voltage 40 V, cone gas 50 L/h, desolvation gas 200 L/h, and nebulizing gas 
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adjusted for most abundant ion currents. The scan mode was MS1 full scan, with mass 
range 360 to 480. [M+6H]
6+
 and [M+5H]
5+ 
peaks of product H3K9 (m/z 376.98 and 
452.13), internal standard H3K9* (m/z 378.65 and 454.24) and substrate H3K9(Ac) (m/z 
383.97 and 460.53) were monitored. The data was acquired by MassLynx (Version 4.1, 
Waters Inc.). 
Calibration of H3K9. A series of H3K9 solutions at different concentrations 
were mixed with single concentration H3K9* solution and different concentration 
H3K9(Ac) solutions. The buffer was 20-fold diluted NAD
+
-Tris buffer. The final 
concentration was: H3K9 0, 0.1, 0.3, 0.5, 0.7 and 1 M; H3K9* 0.5 M; and H3K9(Ac) 
3, 2.9, 2.7, 2.5, 2.3 and 2 M. The mixed solutions were directly pumped into the MS. 
The signal intensity ratio of H3K9 over H3K9* of each solution was plot against the 
concentration of H3K9 using Origin 8.5. 
SIRT6 Kinetic Studies with H3K9(Ac) as Substrate. 2.5 M SIRT6 was added 
into different concentrations of H3K9(Ac) (0 to 150 M). The buffer was the same 
NAD
+
-Tris buffer described above. Reactions were quenched at 0, 1, 2, 3, 4, 5 hours. The 
analysis was performed by uPLC-MS (uPLC: Waters NanoAcquity). The mass 
spectrometer was Agilent 1640 series triple quadrupole MS (Agilent: Santa Clara, CA). 
Mobile phase A contained 0.15% formic acid, 150 mM ammonium formate. Mobile 
phase B was 100% acetonitrile. The linear gradient was: initial, 0% B; 2.01 min, 30% B; 
4 min, 50% B; 4:01 min: 95% B; 8.5 min: 100% B. The amount of product yielded in 
each reaction was calculated based on the peak area of the product and the substrate. The 
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Michaelis-Menten model was fitted by GraphPad Prism 6.01. The reaction progress was 
monitored in the course of 24 hours, with initial 60 substrate and 2.5 M SIRT6. 
Test Screen for Modulators for SIRT6 Deacetylation Activity. A test 
screening involving 25 compounds was performed using 60 M H3K9(Ac) and 2.5 M 
SIRT6. The test compounds were selected from the Epigenetic Screen Library (Cayman 
Chemical, Ann Arbor, MI). The procedure was: 1) 30 L of 11 M SIRT6 was diluted 
into 70 L NAD+-Tris buffer to make Mix A; 1.8 L of 11 M SIRT6 was diluted into 
4.2 L Tris buffer (no NAD+) to make Mix B. 2) 0.5 L of 2 mM test compound (in 10% 
DMSO) was pipetted into a polypropylene 384-well plate (Costar
®
, Corning Inc. 
Tewksbury, MA), occupying well #1-24. 3) 0.5 L 10% DMSO was added into well # 
25-27. 4) 0.5 L of 800 M oleic acid (in 10% DMSO) was added into well #28- 30. 5) 1 
L of 240 M H3K9(Ac) was added into well #1-32. 6) 3 L of Mix A was pipetted into 
well #1-30; 3 L of Mix B was pipetted into well #31-32. The final concentration of each 
assay component was: H3K9(Ac) 60 M, SIRT6 2.5 M, test compounds 25 M and 
DMSO 1.25% (v/v). 7) Sealed and incubated the plate for 4.5 hours. 8) Quenched all 
reactions using 76 L of ice-cold quenchant which contained 30% MeOH, 0.1% formic 
acid and 0.5 M H3K9*. 9) Reformatted quenched reaction mixtures into 3 
droplets/reaction or 1 droplet/reaction droplet array. 10) Infused the droplet array into 
ESI-MS. The detection parameters were the same with above described.  
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The analysis was based on the intensity ratio of H3K9 to H3K9* in each droplet. 
The activator and inhibitor criteria were set as AVE(negative control) ± 3 × SD(negative control). 
Data was processed using Origin 8.5. 
Deacetylation of H3K9(decanoyl) by SIRT6. A 10-mer histone H3K9 lysine 
(decanoyl) (KQTARK(decanoyl)STGG) was used as substrate. SIRT6 was first buffer 
exchanged into formate-DTE buffer using a 10 kD cut-off centrifugal dialysis unit 
Amicon Ultra-0.5 mL (EMD Millipore, Billerica, MA). The procedure and the formate 
buffer were the same with SIRT1 dialysis described in Chapter 4. 20 M H3K9(decanoyl) 
was mixed with 1 M desalted SIRT6 and then incubated at 37oC for 1 hour. The 
reaction was quenched by equal volume ice-cold quenchant which contained isotope 
labeled 10-mer internal standard H3K9(10-mer)*. The reaction mixture was pumped into 
LCQ quadrupole ion trap MS (Thermo Fisher Scientific, Waltham, MA) for analysis. The 
full scan mass range was set as 490-610. Micro-scan was set to be 1. The intensity ratio 
of H3K9(10-mer) to H3K9(10-mer)* was calculated for analysis. 
SIRT6 Kinetic Studies with H3K9(decanoyl) as Substrate. A series of 
H3K9(decanoyl) solutions were mixed with desalted SIRT6. The final concentration of 
the substrate was 0, 5, 10, 20, 40, 80 and 160 M. SIRT6 was 1 M. The reactions were 
incubated in the formate buffer at 37
o
C for 0.5, 1, 2, 4, 6, and 8 h. The ice-cold quenchant 
contained 50% MeOH, 50% H2O, 0.15% formic acid and 5 M isotope-labeled standard 
H3K9(10-mer)* (+8 Da). The analysis was performed by an LCQ MS in full scan. The 
[M+2H]
2+
 peaks for H3K9(10-mer): m/z 517.6, H3K9(10-mer)*: m/z 522.1 and 
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H3K9(decanoyl): m/z 594.7 were monitored. The intensity ratio of H3K9(10-mer) over 
H3K9(10-mer)* was quantified for modeling the Michaelis-Menten curve. 
 
Results and Discussion 
Substrate Selection for SIRT6 Screening. To date, SIRT6 has been proved to 
deacetylate histone H3K9 and histone H3K56,
74,167
 as well as remove the long-chain fatty 
acyl group from the lysine on sequence-independent proteins.
78
 To select proper 
substrates for SIRT6 modulator screening, We investigated the hydrolysis efficiency of 
SIRT6 towards the 3 types of substrates. We chose a 21-mer H3K9(Ac), a 20-mer 
H3K56(Ac) and a 10-mer H3K9(decanoyl) peptides as surrogate substrates. In 
accordance with observation of others, SIRT6 is highly efficient in de-decanoylation. For 
deacetylation, my experiments consistently showed better yield for H3K9(Ac) than 
H3K56(Ac) reactions. Because deacetylation and deacylation might lead to completely 
different biological functions of SIRT6, corresponding modulators could be different. 
Therefore, we will develop assays with both H3K9(Ac) and H3K9(decanoyl). 
SIRT6 Kinetics with H3K9(Ac) as Substrate. The SIRT6 deacetylation reaction 
is shown in Figure 5-1. For a screening, the substrate concentration should be under its 
Km value. The reported Km of H3K9(Ac) peptide is as high as 810 M.
78
 I studied SIRT6 
kinetics with H3K9(Ac) concentration ranging from 0 to 150 M. As expected, the fitted 
Michaelis-Menten model showed that within this range, the initial velocity increased 
linearly (Figure 5-2A). A long-term-incubation experiment showed a very slow catalysis: 
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the reaction yield increased linearly for up to 8 hours before leveling off (Figure 5-2B). 
Based on those results, I chose 60 M H3K9(Ac) and 4.5 h incubation for the screening. 
 
Figure 5-1. Deacetylation of H3K9(Ac) by SIRT6. LC-MS chromatogram showed a 24 h 
incubated reaction (3 M SIRT6, 60 M H3K9(Ac) and 500 M NAD+). The yield was 
only ~20%. 
 
 
Figure 5-2. A) The linear part of Michaelis-Menten model. The velocity linearly 
increased for at least 0-150 M H3K9(Ac), thus the Km should be higher than 75 M. B) 
Reaction progress of SIRT6 deacetylating H3K9(Ac). 
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MS-compatible Deacetylation Assay. Similar to modifying the SIRT1 assay, I 
tried to buffer exchange SIRT6 and then conducted the reaction in the formate buffer. But 
unfortunately, SIRT6 is barely active in ammonium formate, as nearly no product peaks 
were detected by either LC-MS or direct infusion MS. Among all pH 7.5 buffers I have 
tried, including ammonium formate, ammonium acetate, ammonium bicarbonate, 
phosphate, HEPES and Tris, I found that SIRT6 deacetylates most efficiently in Tris 
buffer. High concentration Tris in the sample severely suppresses the signal of all 
analytes, which makes direct infusion impossible. Cleaning up all reactions before 
analysis is one choice to avoid ion suppression, but considering the high cost of SPE 
plates and low throughput, it is desirable to minimize the sample preparation. Another 
choice is diluting the reaction for direct MS analysis.
123
 After trying a range of folds for 
dilution, we found that 20-fold diluted reaction yields relatively abundant peaks of H3K9 
and H3K9*. The unidentified interfering peaks near [M+6H]
6+
 peaks were from the 
buffer which contains Tris, inorganic salts and glycerol (Figure 5-3). Though interfering 
peaks exist, the quantification of H3K9 is not affected (see the calibration curve of H3K9 
in Figure 5-4). Therefore, we plan to use this method for future screenings. 
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Figure 5-3. Direct MS analysis of 20-fold diluted reaction mixture (4.5 h incubation). 
Despite of the presence of noises, peaks of H3K9, H3K9*, and H3K9(Ac) can be 
detected. 
 
 
Figure 5-4. Linear calibration of reaction product H3K9. 0, 0.1, 0.3, 0.5, 0.7 and 1 M of 
H3K9 was calibrated against 0.5 M isotopic internal standard H3K9*. Each solution 
also contained 3, 2.9, 2.7, 2.5, 2.3 and 2 M H3K9(Ac) and 20-fold-diluted NAD+-Tris 
buffer (n = 3). The R
2
 of linearity is 0.998.  
 
SIRT6 Activation by Fatty Acids. Up to now, fatty acids are the only group of 
activators being discovered for SIRT6. 300 M of oleic acid was proved to increase the 
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SIRT6 deacetylation rate by 6 fold.
79
 However, in high throughput screening, the 
concentration of test compound is empirically kept under 30 M, otherwise low solubility, 
aggregation and co-precipitation issues might occur. For direct MS analysis, high 
concentration test compounds affect the ionization efficiency of other analytes, thus we 
tried to lower the concentration of fatty acid to reach a balanced point that abundant 
peptide peaks can be observed and good activation can be achieved. We tried 25, 50, and 
100 M and found that 100 M oleic acid can activate the reaction by about 2 folds, 
which generally agreed with the published dose response experiment.
79
 The mass 
spectrum was noisier than the negative control, but the activation effect was observed as 
the product/substrate ratio was higher (Figure 5-5). 
 
Figure 5-5. Direct MS analysis of 100 M oleic acid activated SIRT6 reaction (4.5 h 
incubation). Compared with the negative control (see Figure 5-3), the yield was twice 
high. 
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Impact of DMSO Nearly all chemical libraries are dissolved in DMSO. The 
tolerance of DMSO of an assay should be evaluated before a screening. For library 
compound depositing, Caliper Life Sciences Sciclone ALH 3000 Workstation 
(PerkinElmer, Waltham, MA) can reliably handle as low as 50 nL solution. Given the 
concentration of the compound stock solution, mostly 2, 5, or 10 mM, at least 1% DMSO 
will be present in a 5 L reaction. We conducted SIRT6 deacetylation reactions with 1%, 
5%, 10% DMSO and 100 M oleic acid (the oleic acid reaction contained 1% DMSO). 
We found that 1% DMSO does not affect the activation effect of the oleic acid. 5% and 
10% DMSO reduce SIRT6 activity, as well as lower the intensity of peptides (Figure 5-
6). Thus, the final concentration of DMSO should be around 1%. Based on this study, 2 
mM library should be used for ~5 L reactions. 
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Figure 5-6. Droplet trace of DMSO evaluation assay (3 droplets/reaction, reactions were 
duplicated). The top trace is product H3K9, the middle is internal standard H3K9*, and 
the bottom is substrate H3K9(Ac). 100 M oleic acid reactions show higher yield than 1% 
DMSO, which means the reactions were activated. 5% and 10% DMSO reactions show 
low yield and low peptide intensity. 
 
Test Screen for Modulators for SIRT6 Deacetylation Activity. 25 compounds 
were screened in this small screening. One of the compound EX-527 was reported to 
inhibit ~60% SIRT6 activity at 200 M.81 Reactions without NAD served as the 
inhibitor control (-), reactions with 100 M oleic acid were the activator control (+), and 
reactions with 1% DMSO were the negative control (0). Both triplicate detection and 
single detection were performed in the same MS run. The droplet traces showed (Figure 
5-7) that the reaction yield in the activator controls was about twice of the negative 
control. The inhibitor controls showed no H3K9 produced. EX-527 reactions (red 
arrows in Figure 5-7) had slightly lower yield than the negative control. We observed 
almost no difference between triplicate and single detection regarding low carryover, 
strong activation effect of oleic acid and weak inhibition effect of EX-527. The analysis 
rate of this screening was 0.7 droplets/s. Z-factor of both triplicate and single detection 
was 0.6. 
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Figure 5-7. Droplet traces of 25-compound test screening. Top to bottom: product H3K9, 
internal standard H3K9*, and substrate H3K9(Ac). Left: triplicate detection in which 
each reaction was made into 3 droplets. Right: single detection for 1 droplet/reaction. (-): 
inhibitor controls in which no NAD
+
 were in the buffer.  (+): activator controls in which 
100 M oleic acid was in the reactions. (0): negative controls in which 1% DMSO was in 
the reactions. Red arrows: reactions with 25 M EX-527. 
 
Analyzing the data using intensity ratio of H3K9/H3K9* proved that at 0.7 Hz, 
the screen result of single detection was very similar to the triplicate detection (Figure 5-
8). The small error bars in the triplicate detection indicate good reliability. For this screen, 
the hit selection standard is AVE(negative control) ± 3 × SD(negative control) (The red line is for the 
activator, and the black line is for the inhibitor). This criterion is less strict than the 50% 
cutoff. Given that only a few SIRT6 modulators have been found, a more tolerant 
standard may pick more hits, which might be developed into strong modulators by further 
modification. In the triplicate detection, only C11 reaction (EX-527) just met the inhibitor 
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had the lowest H3K9/H3K9*. Therefore, we concluded that the 2 detection methods 
generally agreed with each other. Single detection can be used for large scale screening. 
 
Figure 5-8. The analysis of the screening. The y-axis is the intensity ratio of H3K9 over 
H3K9*. The x-axis is compounds ID. The red line is the activator criteria, and the black 
line is the inhibitor criteria. C11 is EX-527 reaction. Triplicate detection means each 
reaction was made into 3 droplets. Single detection means each reaction was made into 1 
droplet. 
 
Efficient Deacylation by SIRT6. SIRT6‟s capability in removing the long fatty 
acyl chain of peptides was reported in 2013.
78
 Regardless of the peptide sequence, such 
deacylation efficiency is hundreds of times greater than deacetylation. For example, the 
Km value of the substrate decreased from about 800 M for H3K9(Ac) to 3 M for 
H3K9(myristoyl).
78
 It suggests the possible involvement of SIRT6 of a totally different 
set of post-translational modification. We selected a 10-residue decanoylated H3K9 as a 
surrogate fatty acylated protein substrate.  Because of the high activity, it is possible to 
perform the reaction in the formate buffer. Figure 5-9 shows the direct MS analysis of a 
1 h incubated reaction (in the ammonium formate-DTE buffer). Nearly 70% substrate 
was converted.  A Tris buffer reaction was performed for comparison. The yield was 
almost 100%. 
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Figure 5-9. Direct infusion the MS-compatible SIRT6 deacylation assay using formate 
buffer. P: product H3K9(10-mer), P*: isotope-labeled internal standard H3K9(10-mer)*, 
S: substrate H3K9(decanoyl). 
 
We also studied the SIRT6 kinetics for de-decanoylation. The fitted Km value is 
27 M (Figure 5-10A). It is higher than other fatty acylated peptides possibly because 
the formate buffer compromised the activity of SIRT6. Fast hydrolysis was observed by 
the shorter linear range of the reaction progress: the maximum yield was achieved in 2 h 
(Figure 5-10B). 
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Figure 5-10. SIRT6 kinetics with 10-mer H3K9(decanoyl) as the substrate. A) 
Michaelis-Menten model. The fitted Km of H3K9(decanoyl) is 27 M. B) Reaction 
progress of SIRT6 de-decanoylation. Reaction rate decreased after 2 h. 
 
Conclusion 
In this work, we have developed 2 mass spectrometry-based SIRT6 assays using 2 
different substrates: H3K9(Ac) and H3K9(decanoyl). Dependent on the hydrolysis 
efficiency of SIRT6, either traditional condition (Tris buffer) or MS-compatible condition 
(formate buffer) was used. Both assays showed adequate yield for large-scale screenings. 
The enzyme kinetic studies suggested appropriate substrate concentration and incubation 
time. Due to the low turnover rate of deacetylation, the substrate H3K9(Ac) is especially 
suitable for activator screening. On the other hand, H3K9(decanoyl) is good for inhibitor 
search. The conditions of the H3K9(Ac) assay were validated by a 25-compound test 
screening. Because H3K9(Ac) is a known endogenous substrate for SIRT6, any 
modulators identified in the screening using the deacetylation assay will be 
physiologically relevant. The H3K9(decanoyl) assay is also interesting because as our 
A)                                                           B) 
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knowledge of SIRT6 building up, it is highly possible that long-chain fatty acylated 
histones naturally exist and sirtuin-relevant. Those substrates are especially suitable for 
finding SIRT6 inhibitors, which are likely to be utilized to treat cancers exacerbated by 
SIRT6. 
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CHAPTER 6 
FUTURE DIRECTIONS 
 
Carryover Reduction of Reagent Addition Chip 
The performance of the all-droplet system (Chapter 1) largely depends on the 
reagent addition chip. High carryover was observed in the original design (PDMS tee), 
thus one sacrificial droplet was necessary for each sample set. To address this issue, we 
proposed an alternative design in which the droplet channel was all Teflon. The later 
reduced the carryover by two thirds.  
There have been several studies on reducing cross-contamination in reagent 
addition. A desired chip design consists of a wide hydrophobic droplet channel and a 
narrow hydrophilic reagent channel. Besides, the linear flow rate of the reagent should be 
higher than the droplets flow.
115
 A multi-channel chip was later reported to perform 
reagent addition in low carryover (almost zero) and high addition ratio (up to 1:1).
32
 
(Figure 6-1) However, we found that those designs are good for surfactant-containing 
biphasic system. Even though many ESI-MS-compatible surfactants have been developed, 
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including acid-labile surfactants and nonionic surfactants, we have noticed that the 
present of surfactant can lower the voltage threshold for spraying the oil in ESI. This 
phenomenon elevates the baseline noise in droplet analysis. Therefore, the use of 
surfactant should be cautious and minimized. As mentioned in Chapter 2, an expansion at 
droplet outlet was constructed for better synchronizing the reagent and droplet flow. The 
trade-off of this expansion is higher carryover.  
 
Figure 6-1. A) Single-channel reagent addition device that reported to have low 
carryover;
115
 B) Multi-channel reagent addition chip.
32
 Reproduced with permission from 
ACS Publications. 
 
Droplet Channel 
Reagent Channel 
A) 
 
 
 
 
 
 
 
 
 
 
 
B) 
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To reduce the carryover, chip geometry, properties of channels‟ inner surface, and 
connections between channels. Potential solutions are: 1) Teflon is very resistant to 
carryover. So it could be beneficial to build a whole Teflon droplet channel with a wider 
outlet; 2) connections between channels should be minimized. Our first design was built 
by inserting 2 pieces of capillaries and 1 piece of Teflon tubing into a PDMS mold. The 
small gaps at the junction contributed to the carryover. For that, one-piece mold will be a 
better design; 3) the competition between convection and diffusion has been used to 
explain the carryover in reagent addition.
32
 Convection injects the reagent into the droplet, 
while carryover is caused by the reagent diffusing out of the droplet. Increasing the linear 
flow rate of the reagent can improve convection and reduce the effective diffusion, and 
thus reduce carryover. This can be achieved by narrowing the reagent channel. 
 
Large-scale All-droplet Enzyme Modulator Screening 
The miniaturizing feature of the all-droplet system will be especially beneficial 
for screenings which involve a large number of assays. Because the cost of reagent 
always limits the scale, conducting all reactions inside droplets can be considerable 
economical. SIRT6 is an expensive and low activity enzyme. It works at micromolar 
level, which is nearly 100-fold higher than the normal concentration of an enzyme in a 
screening. The traditional MWP-based screening usually requires at least 5 L for each 
reaction. Such low volume not only heavily demands the precision and the speed of the 
liquid handling equipment, but also exacerbates the evaporation. Considering the 
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milliliter level dead volume of most automatic liquid dispenser, the expense for SIRT6 is 
forbidden. Besides, transferring reagents and samples by MWP-based HTS equipment 
costs a large amount of pipette tips. In contrast, a built-in-house all-droplet system 
requires only nanoliters of reaction volume, does not have evaporation issue, has no dead 
volume and needs no transfer. Table 6-1 compares the reagent consumption and cost for 
an MWP-based SIRT6 modulator screening and an all-droplet-system-based screen. 
Table 6-1. Comparison between MWP-based SIRT6 modulator screening and all-
droplet-system-based screening. (SIRT6 is 3 M/reaction, ~$270/nanomole; H3K9(Ac) is 
50 M/reaction, ~$0.5/nanomole; H3K9* is 0.5 M/diluted reaction, ~$1.5/nanomole). 
 MWP-based screen All-droplet screen 
Number of reactions 10000 10000 
Reaction Volume 4 L 10 nL 
Dead volume of dispenser  3 mL 0 
SIRT6 (4 M stock)  consumption 33 mL 75 L 
H3K9(Ac) (200 M stock) consumption 13 mL 25 L 
H3K9* (200 M stock) consumption 2 mL 5 L 
Total cost of SIRT6 $36000 $81 
Total cost of H3K9(Ac) $1300 $2.5 
Total cost of H3K9* $600 $1.5 
Cost of pipette tips $2000 0 
Total cost $40000 $85 
 
Currently, we are exploring miniaturizing SIRT6 modulator screening by 
implementing a microfabricated multi-step reaction addition device. A temporary design 
is a multi-channel reagent addition PDMS chip. The droplet channel will be fluorinated 
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polymer-coated PDMS. The screening will be explored either by a fluorescent assay 
(with a fluorescent label far away from the acetylated lysine) or a MS assay.  
To save the compounds from the libraries, a droplet splitter
31
 can be hyphenated 
to the droplet flow. Samples can be aspirated from MWPs into large plugs and then split 
into two daughter plugs with designated splitting ratio. One of the daughter plugs can be 
introduced into the all-droplet system for enzymatic assay. The other plug can go through 
a different assay which yields complementary results, or be stored as droplet library for 
future use. 
 
Automation of Mass Spectrometry Plate Reader 
To realize large-scale high throughput screening by the MS plate reader, 
automation of the system will be explored. In sample-droplet reformatting step, tube 
alignment should be precisely controlled by a computer. Because the perfluorinated oil 
on top of the plate is very thin, it is necessary to ensure all sippers start from the right 
height. For infusing sample droplets into ESI-MS, sample tubes (FEP) are now switched 
by hand, and the interface between the sample tube and the ESI housing requires 
screwing in a union head. A smoother interface can reduce the force applied on the 
sample tube, which lowers the possibility to crash the droplets inside and also facilitates 
automatic manipulator for tube switching. With all steps fully automated, the MS plate 
reader has a potential to analyzed nearly 150,000 samples in 24 hours.  
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Sample Cleanup 
Droplet-ESI-MS systems can be improved by adding a step of sample preparation 
prior to either droplet generation or MS analysis. Removing the salts and high 
concentration buffer components can improve the quality of mass spectra, increase the 
signal to noise ratio of the target analytes, lower the demand on high reagent 
concentration, and prolong the lifetime of the instrument.  
One way to clean up the sample is utilizing high throughput solid phase extraction 
(SPE) plates before droplet generation. There are 96 and 384-well SPE plates 
commercially available. The extraction phase is usually reverse phase material, either 
hydrophobic filters or common separation media (Figure 6-2A, B). Coated-magnetic 
beads have also been proved efficacious (Figure 6-2C).
168
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Figure 6-2. Solid phase extraction plates. A) Filter-based SPE plate (3M Empore
TM
: each 
well of the plate contains a standard density Empore
TM
 polypropylene membrane for 
efficient sample extraction). B) Particle-based SPE plate (Glysci Slit Plate
TM
: separation 
media is filter-less chromatographic particles. A 1-2 m slit at the bottom of each well in 
Slit Plate permits liquid to pass through). C) Magnetic beads-based SPE (Xiril AG 
Magnetic Plate-X: separation particles are coated on magnetic beads residing in each well. 
Separation is realized by attracting beads to the corner of each well of the assay plate by 
the magnets array inserted under the assay plate). 
 
A) 
 
 
 
 
 
 
 
 
 
B) 
 
 
 
 
 
 
C) 
3M Patent 
Polypropylene 
Filter 
Slit 
Slit 
Sample 
Chromatographic Media 
  Coated Magnetic Beads 
Magnets 
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We have tried parallel sample preparation using multiple C18 spin columns. The 
whole process was finished in 3 min (1 min spin for binding, 1 min for washing and 1 
min for eluting). High quality mass spectra were obtained. Product peaks from a low-
yield reactions were observed, which would be very difficult for direct infusion of the 
untreated reaction mixture (Figure 6-3) 
 
Figure 6-3. Comparison of mass spectra of the desalted reaction (left, desalted by C-18 
spin column, undiluted) and the intact reaction mixture (right, diluted by 20 folds in order 
to observe peptides). The noise level of treated reaction is significantly lower. Despite the 
low yield, product peaks are observed in the desalted reaction mass spectrum. 
 
Another sample cleaning method is to engineering an extraction bed inside the 
needle. Our group has explored the possibility of packing a short C18 chromatographic 
bed into the rear end of a nanospray tip. The target analyte partitions into the stationary 
phase when a sample plug passes through the bed. The water droplet coming later washes 
off the soluble impurities. Then an eluting droplet containing organic solvent elutes the 
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analyte out of the bed and transfers it into ESI-MS. Different samples can be separated by 
another water droplet as a „wash‟ to prevent cross-contamination (Figure 6-4).169 
 
Figure 6-4. Top: scheme of droplet-based SPE. Bottom: total ion current of sequentially 
injected 4 samples.
169
 Reproduced with permission from Qiang Li and University of 
Michigan. 
 
Tracking a Screening 
Because the data output in segmented-flow-based screening is a series of droplet 
trace, tracking a screen requires translating the sequence of droplets back to the position 
on the MWPs. If any miscounting occurs, wrong hits will be picked. This problem can be 
solved by taking advantage of the multiplexing ability of MS: detecting multiple 
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compounds simultaneously. For HTS, a rapid MS scan covering certain range of m/z can 
not only monitor the target analytes, but also identify compounds which have an effect on 
the enzyme (see examples in Chapter 2). It saves time for back tracking the assay based 
on the order. Though for a triple quadrupole MS, full scan is generally slower than MRM, 
the lower speed can be overcome by using a fast spectrometer, such as time-of-flight 
(TOF) MS. A standard TOF-MS can scan 1000 Da in 10-20 ms. Based on our experience, 
10-12 data points per droplet-oil pair ensure reproducible droplet trace. 20 ms/spectrum 
enables at least 4 Hz analysis. 
 
Custom Data Analysis Program 
Facing the vast dataset produced by a screening, data analysis can be rate limiting. 
A customized droplet-ESI-MS screening analysis software should be able to: 
1) Smooth out the droplet peaks. Signal fluctuation is a common phenomenon in 
ESI-MS. Peak picking software such as Origin 8.5 will mistakenly identify one droplet 
peak as multiple if droplets are not appropriately smoothed. Signal spikes are expected 
when ESI is turned on and off at high frequency. A proper program to remove the 
artificial spikes would facilitate the peak identification. Besides, the smoothing needs to 
preserve the real peak height of each droplet, otherwise quantification will be 
compromised. 
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2) Reliably pick high throughput droplet peaks from extract ion current. Any 
shoulder peak or occasionally high noise between sample droplets should be ignored. 
Any split-top droplet peak which is not completely smoothed out should be identified as 
one peak. In a large-scale screening, tens of thousands of droplet peaks will be collected. 
The order of the droplet corresponds to the sample position on MWPs. It is crucial to 
ensure a correct order.  
3) Automatically calculate the intensity (peak height) ratio of the target analyte 
over its internal standard and identify promising hits based on built-in criteria. Common 
criteria include percent of inhibition/activation, z-score, strictly standardized mean 
difference (SSMD) and t-statistic.
170,171
 Percent of inhibition/activation is most 
straightforward, but it doesn‟t take data variability into account. Z-score method assumes 
standard normal distribution. Z-score equals mean ± k SD (standard deviation), where k is 
usually set as 2 or 3. SSMD is defined as the ratio of mean to standard deviation of the 
test sample and the negative control. The t-statistic is suitable for screens with replicates, 
in which the p-value is dependent on both the effect and the sample size. The software 
should be programmed with all established statistical methods at researcher‟s 
convenience. After hits selection, the software should be able to design replicated assays 
or dose dependent experiments.  
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APPENDICES 
APPENDIX A 
Sequence of test compounds in Cathepsin B Assay 
1. In-well Cathepsin B inhibitor screening using ZRR-AMC as substrate 
The sequence of 23 test compounds and a non-inhibitor control is E-64, leupeptin, 
antipain, control, methionine, arginine, tyrosine, histamine, thyronine, proline, lysine, 
valine, asparagine, tryptophan, isoleucine, leucine, phenylalanine, cysteine, aspartic acid, 
GABA, serine, glycine, acetylcholine, adenosine. 
2. In-well screening using Ac-GFGFVGG-NH2 as substrate 
The sequence of 11 test compounds and a non-inhibitor control is E-64, leupeptin, 
antipain, control, methionine, arginine, tyrosine, thyronine, proline, lysine, phenylalanine, 
asparagine, GABA. 
3. All-droplet screening using ZRR-AMC as substrate with PDMS tees 
The sequence of 24 test compounds and the non-inhibitor control is control, antipain, 
cysteine, phenylalanine, leucine, lysine, proline, asparagine, E-64, valine, adenosine, 
acetylcholine, glycine, serine, GABA, aspartic acid, leupeptin, isoleucine, tryptophan, 
thyronine, histamine, tyrosine, arginine, methionine, p-nitrophenol.  
4. All-droplet screening using Ac-GFGFVGG-NH2 as substrate with Teflon tees 
One control and three test compounds are in 9 replicates, and two inhibitors are in 8 
replicates. The sequence is: control, E-64, tyrosine, thyronine, leupeptin, and proline. 
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APPENDIX B 
Goodness of Fit of Inhibitor Hits in Cathepsin B Inhibitor Screening 
Hits R
2
 
cefmetazole 0.9875 
diacerein 0.9471 
ethacrynic acid 0.9630 
avobenzone 0.9757 
hexachlorophene 0.9473 
zafirlukast 0.9594 
metergolin 0.9350 
butenafine 0.9205 
triclosan 0.9478 
diethylstilbestrol 0.9357 
anthralin 0.9333 
thioguanosine 0.9248 
pimozide 0.9315 
didanosine 0.9196 
luteolin 0.9266 
alexidine 0.9518 
colistin 0.9391 
disulfiram 0.9429 
triclabendazole 0.9356 
raloxifene 0.9587 
pinaverium 0.9557 
chlorhexidine 0.9688 
tegaserod 0.9711 
cefaclor 0.9648 
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APPENDIX C 
Structures of Inhibitor Hits in Cathepsin B Inhibitor Screening 
Hits Structure 
cefmetazole  
diacerein  
ethacrynic acid  
avobenzone  
hexachlorophene  
zafirlukast  
metergolin   
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butenafine  
triclosan  
diethylstilbestrol  
anthralin  
thioguanosine  
pimozide  
didanosine  
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luteolin  
alexidine  
colistin  
disulfiram  
triclabendazole  
raloxifene  
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pinaverium  
chlorhexidine  
tegaserod  
cefaclor  
  
 127 
 
 
 
 
REFERENCES 
 
(1) Inglese, J.; Johnson, R. L.; Simeonov, A.; Xia, M.; Zheng, W.; Austin, C. P.; Auld, D. 
S. Nat. Chem. Biol. 2007, 3, 466-479. 
(2) Gomez-Hens, A.; Aguilar-Caballos, M. P. TrAC, Trends Anal. Chem. 2007, 26, 171-
182. 
(3) de Boer, A. R.; Lingeman, H.; Niessen, W. M. A.; Irth, H. TrAC, Trends Anal. Chem. 
2007, 26, 867-883. 
(4) Kassel, D. B. Chem. Rev. 2001, 101, 255-267. 
(5) von Ahsen, O.; Bomer, U. Chembiochem 2005, 6, 481-490. 
(6) Shiau, A. K.; Massari, M. E.; Ozbal, C. C. Comb. Chem. High Throughput Screen 
2008, 11, 231-237. 
(7) Cunningham, B. T.; Laing, L. G. Expert Opin. Drug Dis. 2008, 3, 891-901. 
(8) Hsieh, F.; Keshishian, H.; Muir, C. J. Biomol. Screening 1998, 3, 189-198. 
(9) Konermann, L.; Ahadi, E.; Rodriguez, A. D.; Vahidi, S. Anal. Chem. 2013, 85, 2-9. 
(10) Wu, X.; Oleschuk, R. D.; Cann, N. M. Analyst 2012, 137, 4150-4161. 
(11) Annesley, T. M. Clin. Chem. 2003, 49, 1041-1044. 
(12) Jessome, L. L.; Volmer, D. A. Lc Gc North America 2006, 24, 498-+. 
(13) Furey, A.; Moriarty, M.; Bane, V.; Kinsella, B.; Lehane, M. Talanta 2013, 115, 104-
122. 
(14) Ackermann, B. L.; Berna, M. J.; Eckstein, J. A.; Ott, L. W.; Chaudhary, A. K. Annu. 
Rev. Anal. Chem. 2008, 1, 357-396. 
(15) Maurer, H. H.; Peters, F. T. Ther. Drug Monit. 2005, 27, 686-688. 
(16) Roddy, T. P.; Horvath, C. R.; Stout, S. J.; Kenney, K. L.; Ho, P. I.; Zhang, J. H.; 
Vickers, C.; Kaushik, V.; Hubbard, B.; Wang, Y. K. Anal. Chem. 2007, 79, 8207-8213. 
(17) Annis, D. A.; Nazef, N.; Chuang, C.-C.; Scott, M. P.; Nash, H. M. J. Am. Chem. Soc. 
2004, 126, 15495-15503. 
 128 
 
(18) Comess, K. M.; Schurdak, M. E.; Voorbach, M. J.; Coen, M.; Trumbull, J. D.; Yang, 
H.; Gao, L.; Tang, H.; Cheng, X.; Lerner, C. G.; Mccall, J. O.; Burns, D. J.; Beutel, B. A. 
J. Biomol. Screening 2006, 11, 743-754. 
(19) Leveridge, M.; Buxton, R.; Argyrou, A.; Francis, P.; Leavens, B.; West, A.; Rees, 
M.; Hardwicke, P.; Bridges, A.; Ratcliffe, S.; Chung, C. J. Biomol. Screening 2014, 19, 
278-286. 
(20) Oellig, C.; Schwack, W. J. Chromatogr. A 2014, 1351, 1-11. 
(21) Pavlic, M.; Schubert, B.; Libiseller, K.; Oberacher, H. Forensic Sci. Int. 2010, 197, 
40-47. 
(22) Fuhrer, T.; Heer, D.; Begemann, B.; Zamboni, N. Anal. Chem. 2011, 83, 7074-7080. 
(23) Morand, K. L.; Burt, T. M.; Regg, B. T.; Chester, T. L. Anal. Chem. 2000, 73, 247-
252. 
(24) Roddy, T. P.; Horvath, C. R.; Stout, S. J.; Kenney, K. L.; Ho, P.; Zhang, J.; Vickers, 
C.; Kaushik, V.; Hubbard, B.; Wang, Y. K. Anal. Chem. 2007, 79, 8207-8213. 
(25) Jonker, N.; Kool, J.; Irth, H.; Niessen, W. A. Anal. Bioanal.Chem. 2011, 399, 2669-
2681. 
(26) Theberge, A. B.; Courtois, F.; Schaerli, Y.; Fischlechner, M.; Abell, C.; Hollfelder, 
F.; Huck, W. T. S. Angew. Chem. Int. Ed. 2010, 49, 5846-5868. 
(27) Trivedi, V.; Doshi, A.; Kurup, G. K.; Ereifej, E.; Vandevord, P. J.; Basu, A. S. Lab 
Chip 2010, 10, 2433-2442. 
(28) Baret, J.-C. Lab Chip 2012, 12, 422-433. 
(29) Macarron, R.; Hertzberg, R. P. Molecular Biotechnology 2011, 47, 270-285. 
(30) Agresti, J. J.; Antipov, E.; Abate, A. R.; Ahn, K.; Rowat, A. C.; Baret, J.-C.; 
Marquez, M.; Klibanov, A. M.; Griffiths, A. D.; Weitz, D. A. Proc. Nat. Acad. Sci. U.S.A. 
2010. 
(31) Nie, J.; Kennedy, R. T. Anal. Chem. 2010, 82, 7852-7856. 
(32) Li, L.; Boedicker, J. Q.; Ismagilov, R. F. Anal. Chem. 2007, 79, 2756-2761. 
(33) Niu, X.; Gielen, F.; Edel, J. B.; deMello, A. J. Nature Chemistry 2011, 3, 437-442. 
(34) Hatakeyama, T.; Chen, D. L.; Ismagilov, R. F. J. Am. Chem. Soc. 2006, 128, 2518-
2519. 
(35) Cho, S.; Kang, D. K.; Sim, S.; Geier, F.; Kim, J. Y.; Niu, X. Z.; Edel, J. B.; Chang, S. 
I.; Wootton, R. C. R.; Elvira, K. S.; deMello, A. J. Anal. Chem. 2013, 85, 8866-8872. 
(36) Zheng, B.; Roach, L. S.; Ismagilov, R. F. J. Am. Chem. Soc. 2003, 125, 11170-
11171. 
(37) Miller, O. J.; El Harrak, A.; Mangeat, T.; Baret, J. C.; Frenz, L.; El Debs, B.; Mayot, 
E.; Samuels, M. L.; Rooney, E. K.; Dieu, P.; Galvan, M.; Link, D. R.; Griffiths, A. D. 
Proc. Nat. Acad. Sci. U.S.A. 2012, 109, 378-383. 
 129 
 
(38) Kelly, R. T.; Page, J. S.; Marginean, I.; Tang, K.; Smith, R. D. Angew. Chem. Int. Ed. 
2009, 48, 6832-6835. 
(39) Fidalgo, L. M.; Whyte, G.; Ruotolo, B. T.; Benesch, J. L. P.; Stengel, F.; Abell, C.; 
Robinson, C. V.; Huck, W. T. S. Angew. Chem. Int. Ed. 2009, 48, 3665-3668. 
(40) Pei, J.; Li, Q.; Lee, M. S.; Valaskovic, G. A.; Kennedy, R. T. Anal. Chem. 2009, 81, 
6558-6561. 
(41) Pei, J.; Li, Q.; Kennedy, R. T. J. Am. Soc. Mass. Spectrom. 2010, 21, 1107-1113. 
(42) Li, Q.; Pei, J.; Song, P.; Kennedy, R. T. Anal. Chem. 2010, 82, 5260-5267. 
(43) Mohamed, M. M.; Sloane, B. F. Nat. Rev. Cancer 2006, 6, 764-775. 
(44) Mort, J. S.; Buttle, D. J. Int. J. Biochem. Cell Biol. 1997, 29, 715-720. 
(45) Tomoo, K. Curr. Top. Med. Chem. 2010, 10, 696-707. 
(46) Sloane, B. F.; Yan, S.; Podgorski, I.; Linebaugh, B. E.; Cher, M. L.; Mai, J.; 
Cavallo-Medved, D.; Sameni, M.; Dosescu, J.; Moin, K. Sem. Cancer Biol, 2005, 15, 
149-157. 
(47) Gondi, C. S.; Rao, J. S. Expert Opin. Ther. Tar. 2013, 17, 281-291. 
(48) Vasiljeva, O.; Reinheckel, T.; Peters, C.; Turk, D.; Turk, V.; Turk, B. Curr. Pharm. 
Des. 2007, 13, 387-403. 
(49) Bell-McGuinn, K. M.; Garfall, A. L.; Bogyo, M.; Hanahan, D.; Joyce, J. A. Cancer 
Res. 2007, 67, 7378-7385. 
(50) Withana, N. P.; Blum, G.; Sameni, M.; Slaney, C.; Anbalagan, A.; Olive, M. B.; 
Bidwell, B. N.; Edgington, L.; Wang, L.; Moin, K.; Sloane, B. F.; Anderson, R. L.; 
Bogyo, M. S.; Parker, B. S. Cancer Res. 2012, 72, 1199-1209. 
(51) Smooker, P. M.; Jayaraj, R.; Pike, R. N.; Spithill, T. W. Trends Parasitol. 2010, 26, 
506-514. 
(52) Požgan, U.; Caglič, D.; Rozman, B.; Nagase, H.; Turk, V.; Turk, B. In Biol. Chem. , 
2010, p 571. 
(53) Sun, B.; Zhou, Y.; Halabisky, B.; Lo, I.; Cho, S.-H.; Mueller-Steiner, S.; Devidze, 
N.; Wang, X.; Grubb, A.; Gan, L. Neuron 2008, 60, 247-257. 
(54) Sundelöf, J.; Sundström, J.; Hansson, O.; Eriksdotter-Jönhagen, M.; Giedraitis, V.; 
Larsson, A.; Degerman-Gunnarsson, M.; Ingelsson, M.; Minthon, L.; Blennow, K.; 
Kilander, L.; Basun, H.; Lannfelt, L. J. Alzheimers Dis. 2010, 22, 1223-1230. 
(55) Hook, V.; Funkelstein, L.; Wegrzyn, J.; Bark, S.; Kindy, M.; Hook, G. Biochimica et 
Biophysica Acta (BBA) - Proteins and Proteomics 2012, 1824, 89-104. 
(56) Hall, J. A.; Dominy, J. E.; Lee, Y.; Puigserver, P. J. Clin. Invest. 2013, 123, 973-979. 
(57) Chang, H.; Guarente, L. Trends Endocrin Met 2014, 25, 138-145. 
 130 
 
(58) Satoh, A.; Brace, Cynthia S.; Rensing, N.; Cliften, P.; Wozniak, David F.; Herzog, 
Erik D.; Yamada, Kelvin A.; Imai, S. Cell Metab. 2013, 18, 416-430. 
(59) Howitz, K. T.; Bitterman, K. J.; Cohen, H. Y.; Lamming, D. W.; Lavu, S.; Wood, J. 
G.; Zipkin, R. E.; Chung, P.; Kisielewski, A.; Zhang, L. L.; Scherer, B.; Sinclair, D. A. 
Nature 2003, 425, 191-196. 
(60) Hubbard, B. P.; Sinclair, D. A. Trends Pharmacol. Sci. 2014, 35, 146-154. 
(61) Milne, J. C.; Lambert, P. D.; Schenk, S.; Carney, D. P.; Smith, J. J.; Gagne, D. J.; Jin, 
L.; Boss, O.; Perni, R. B.; Vu, C. B.; Bemis, J. E.; Xie, R.; Disch, J. S.; Ng, P. Y.; Nunes, 
J. J.; Lynch, A. V.; Yang, H. Y.; Galonek, H.; Israelian, K.; Choy, W.; Iffland, A.; Lavu, 
S.; Medvedik, O.; Sinclair, D. A.; Olefsky, J. M.; Jirousek, M. R.; Elliott, P. J.; Westphal, 
C. H. Nature 2007, 450, 712-716. 
(62) Lagouge, M.; Argmann, C.; Gerhart-Hines, Z.; Meziane, H.; Lerin, C.; Daussin, F.; 
Messadeq, N.; Milne, J.; Lambert, P.; Elliott, P.; Geny, B.; Laakso, M.; Puigserver, P.; 
Auwerx, J. Cell 2006, 127, 1109-1122. 
(63) Feige, J. N.; Lagouge, M.; Canto, C.; Strehle, A.; Houten, S. M.; Milne, J. C.; 
Lambert, P. D.; Mataki, C.; Elliott, P. J.; Auwerx, J. Cell Metab. 2008, 8, 347-358. 
(64) Mitchell, S. J.; Martin-Montalvo, A.; Mercken, E. M.; Palacios, H. H.; Ward, T. M.; 
Abulwerdi, G.; Minor, R. K.; Vlasuk, G. P.; Ellis, J. L.; Sinclair, D. A.; Dawson, J.; 
Allison, D. B.; Zhang, Y. Q.; Becker, K. G.; Bernier, M.; de Cabo, R. Cell Rep. 2014, 6, 
836-843. 
(65) Yi, Y. W.; Kang, H. J.; Kim, H. J.; Kong, Y. L.; Brown, M. L.; Bae, I. Oncotarget 
2013, 4, 984-994. 
(66) Yamazaki, Y.; Usui, I.; Kanatani, Y.; Matsuya, Y.; Tsuneyama, K.; Fujisaka, S.; 
Bukhari, A.; Suzuki, H.; Senda, S.; Imanishi, S.; Hirata, K.; Ishiki, M.; Hayashi, R.; 
Urakaze, M.; Nemoto, H.; Kobayashi, M.; Tobe, K. Am. J. Physiol.-Endocrinol. Metab. 
2009, 297, E1179-E1186. 
(67) Kaeberlein, M.; McDonagh, T.; Heltweg, B.; Hixon, J.; Westman, E. A.; Caldwell, S. 
D.; Napper, A.; Curtis, R.; DiStefano, P. S.; Fields, S.; Bedalov, A.; Kennedy, B. K. J. 
Biol. Chem. 2005, 280, 17038-17045. 
(68) Pacholec, M.; Chrunyk, B. A.; Cunningham, D.; Flynn, D.; Griffith, D. A.; Griffor, 
M.; Loulakis, P.; Pabst, B.; Qiu, X.; Stockman, B.; Thanabal, V.; Varghese, A.; Ward, J.; 
Withka, J.; Ahn, K. J. Biol. Chem. 2010. 
(69) Beher, D.; Wu, J.; Cumine, S.; Kim, K. W.; Lu, S.; Atangan, L.; Wang, M. Chem. 
Bio. Drug Des. 2009, 74, 619-624. 
(70) Borra, M. T.; Smith, B. C.; Denu, J. M. J. Biol. Chem. 2005, 280, 17187-17195. 
(71) Hubbard, B. P.; Gomes, A. P.; Dai, H.; Li, J.; Case, A. W.; Considine, T.; Riera, T. 
V.; Lee, J. E.; E, S. Y.; Lamming, D. W.; Pentelute, B. L.; Schuman, E. R.; Stevens, L. 
A.; Ling, A. J. Y.; Armour, S. M.; Michan, S.; Zhao, H.; Jiang, Y.; Sweitzer, S. M.; Blum, 
 131 
 
C. A.; Disch, J. S.; Ng, P. Y.; Howitz, K. T.; Rolo, A. P.; Hamuro, Y.; Moss, J.; Perni, R. 
B.; Ellis, J. L.; Vlasuk, G. P.; Sinclair, D. A. Science 2013, 339, 1216-1219. 
(72) Dai, H.; Kustigian, L.; Carney, D.; Case, A.; Considine, T.; Hubbard, B.; Perni, R.; 
Riera, T.; Szczepankiewicz, B.; Vlasuk, G.; Stein, R. J. Biol. Chem. 2010, 285, 32695-
32703. 
(73) Michan, S.; Sinclair, D. Biochem. J 2007, 404, 1-13. 
(74) Michishita, E.; McCord, R. A.; Berber, E.; Kioi, M.; Padilla-Nash, H.; Damian, M.; 
Cheung, P.; Kusumoto, R.; Kawahara, T. L. A.; Barrett, J. C.; Chang, H. Y.; Bohr, V. A.; 
Ried, T.; Gozani, O.; Chua, K. F. Nature 2008, 452, 492-U416. 
(75) Kanfi, Y.; Naiman, S.; Amir, G.; Peshti, V.; Zinman, G.; Nahum, L.; Bar-Joseph, Z.; 
Cohen, H. Y. Nature 2012, 483, 218-221. 
(76) Gertler, A. A.; Cohen, H. Y. Biogerontology 2013, 14, 629-639. 
(77) Masri, S.; Rigor, P.; Cervantes, M.; Ceglia, N.; Sebastian, C.; Xiao, C. Y.; Roqueta-
Rivera, M.; Deng, C. X.; Osborne, T. F.; Mostoslavsky, R.; Baldi, P.; Sassone-Corsi, P. 
Cell 2014, 158, 659-672. 
(78) Jiang, H.; Khan, S.; Wang, Y.; Charron, G.; He, B.; Sebastian, C.; Du, J.; Kim, R.; 
Ge, E.; Mostoslavsky, R.; Hang, H. C.; Hao, Q.; Lin, H. Nature 2013, 496, 110-113. 
(79) Feldman, J. L.; Baeza, J.; Denu, J. M. J. Biol. Chem. 2013, 288, 31350-31356. 
(80) Hu, J.; He, B.; Bhargava, S.; Lin, H. N. Org. Biomol. Chem. 2013, 11, 5213-5216. 
(81) Kokkonen, P.; Rahnasto-Rilla, M.; Mellini, P.; Jarho, E.; Lahtela-Kakkonen, M.; 
Kokkola, T. Eur. J. Pharm. Sci. 2014, 63, 71-76. 
(82) Sun, S.; Slaney, T. R.; Kennedy, R. T. Anal. Chem. 2012, 84, 5794-5800. 
(83) Sun, S.; Kennedy, R. T. Anal. Chem. 2014, 86, 9309-9314. 
(84) Casadevall i Solvas, X.; deMello, A. Chem. Commun. 2011, 47, 1936-1942. 
(85) Chiu, D. T.; Lorenz, R. M. Acc. Chem. Res. 2009, 42, 649-658. 
(86) Furman, W. B. Continuous-Flow Analysis. Theory and Practice: New York, 1976. 
(87) Abate, A. R.; Hung, T.; Mary, P.; Agresti, J. J.; Weitz, D. A. Proc. Nat. Acad. Sci. 
U.S.A. 2010, 107, 19163-19166. 
(88) Song, H.; Chen, D. L.; Ismagilov, R. F. Angew. Chem.-Int. Edit. 2006, 45, 7336-
7356. 
(89) Adamson, D. N.; Mustafi, D.; Zhang, J. X. J.; Zheng, B.; Ismagilov, R. F. Lab Chip 
2006, 6, 1178-1186. 
(90) Abate, A. R.; Agresti, J. J.; Weitz, D. A. Appl. Phys. Lett. 2010, 96. 
(91) Ahn, B.; Lee, K.; Panchapakesan, R.; Oh, K. W. Biomicrofluidics 2011, 5. 
(92) Cai, L. F.; Zhu, Y.; Du, G. S.; Fang, Q. Anal. Chem. 2012, 84, 446-452. 
 132 
 
(93) Pei, J.; Nie, J.; Kennedy, R. T. Anal. Chem. 2010, 82, 9261-9267. 
(94) Ahn, K.; Agresti, J.; Chong, H.; Marquez, M.; Weitz, D. A. Appl. Phys. Lett. 2006, 
88. 
(95) Mazutis, L.; Baret, J. C.; Treacy, P.; Skhiri, Y.; Araghi, A. F.; Ryckelynck, M.; Taly, 
V.; Griffiths, A. D. Lab Chip 2009, 9, 2902-2908. 
(96) Roach, L. S.; Song, H.; Ismagilov, R. F. Anal. Chem. 2005, 77, 785-796. 
(97) Srisa-Art, M.; Dyson, E. C.; deMello, A. J.; Edel, J. B. Anal. Chem. 2008, 80, 7063-
7067. 
(98) He, M.; Edgar, J. S.; Jeffries, G. D. M.; Lorenz, R. M.; Shelby, J. P.; Chiu, D. T. 
Anal. Chem. 2005, 77, 1539-1544. 
(99) Clausell-Tormos, J.; Lieber, D.; Baret, J. C.; El-Harrak, A.; Miller, O. J.; Frenz, L.; 
Blouwolff, J.; Humphry, K. J.; Koster, S.; Duan, H.; Holtze, C.; Weitz, D. A.; Griffiths, 
A. D.; Merten, C. A. Chem. Biol. 2008, 15, 875-875. 
(100) Shim, J. U.; Olguin, L. F.; Whyte, G.; Scott, D.; Babtie, A.; Abell, C.; Huck, W. T. 
S.; Hollfelder, F. J. Am. Chem. Soc. 2009, 131, 15251-15256. 
(101) Kreutz, J. E.; Shukhaev, A.; Du, W. B.; Druskin, S.; Daugulis, O.; Ismagilov, R. F. 
J. Am. Chem. Soc. 2010, 132, 3128-3132. 
(102) Lunn, C. A. Future Med. Chem. 2010, 2, 1703-1716. 
(103) Zhu, Y.; Fang, Q. Anal. Chem. 2010, 82, 8361-8366. 
(104) Hook, V.; Funkelstein, L.; Wegrzyn, J.; Bark, S.; Kindy, M.; Hook, G. Biochim. 
Biophys. Acta, Proteins Proteomics 2012, 1824, 89-104. 
(105) Sevenich, L.; Schurigt, U.; Sachse, K.; Gajda, M.; Werner, F.; Muller, S.; Vasiljeva, 
O.; Schwinde, A.; Klemm, N.; Deussing, J.; Peters, C.; Reinheckel, T. Proc Natl Acad 
Sci U S A 2010, 107, 2497-2502. 
(106) Pozgan, U.; Caglic, D.; Rozman, B.; Nagase, H.; Turk, V.; Turk, B. Biol. Chem. 
2010, 391, 571-579. 
(107) Jilkova, A.; Rezacova, P.; Lepsik, M.; Horn, M.; Vachova, J.; Fanfrlik, J.; Brynda, 
J.; McKerrow, J. H.; Caffrey, C. R.; Mares, M. J. Biol. Chem. 2011, 286, 35770-35781. 
(108) de Boer, A. R.; Letzel, T.; van Elswijk, D. A.; Lingeman, H.; Niessen, W. M. A.; 
Irth, H. Anal. Chem. 2004, 76, 3155-3161. 
(109) Slaney, T. R.; Nie, J.; Hershey, N. D.; Thwar, P. K.; Linderman, J.; Burns, M. A.; 
Kennedy, R. T. Anal. Chem. 2011, 83, 5207-5213. 
(110) McDonald, J. C.; Whitesides, G. M. Acc. Chem. Res. 2002, 35, 491-499. 
(111) Biniossek, M. L.; Nägler, D. K.; Becker-Pauly, C.; Schilling, O. J. Proteome Res. 
2011, 10, 5363-5373. 
(112) Gosalia, D. N.; Salisbury, C. M.; Ellman, J. A.; Diamond, S. L. Mol. Cell 
Proteomics 2005, 4, 626-636. 
 133 
 
(113) Zhang, J. H.; Chung, T. D. Y.; Oldenburg, K. R. J. Biomol. Screening 1999, 4, 67-
73. 
(114) Sivasamy, J.; Chim, Y. C.; Wong, T.-N.; Nguyen, N.-T.; Yobas, L. Microfluid. 
Nanofluid. 2009, 8, 409-416. 
(115) Song, H.; Li, H. W.; Munson, M. S.; Van Ha, T. G.; Ismagilov, R. F. Anal. Chem. 
2006, 78, 4839-4849. 
(116) Zehender, H.; Mayr, L. M. Curr. Opin. Chem. Biol. 2007, 11, 511-517. 
(117) Zehender, H.; Le Goff, F.; Lehmann, N.; Filipuzzi, I.; Mayr, L. M. J. Biomol. 
Screening 2004, 9, 498-505. 
(118) Khandekar, S. S.; Feng, B.; Yi, T.; Chen, S.; Laping, N.; Bramson, N. J. Biomol. 
Screening 2005, 10, 447-455. 
(119) Price, A. K.; MacConnell, A. B.; Paegel, B. M. Anal. Chem. 2014, 86, 5039-5044. 
(120) Bodnarchuk, M. I.; Li, L.; Fok, A.; Nachtergaele, S.; Ismagilov, R. F.; Talapin, D. 
V. J. Am. Chem. Soc. 2011, 133, 8956-8960. 
(121) Sgro, A. E.; Allen, P. B.; Chiu, D. T. Anal. Chem. 2007, 79, 4845-4851. 
(122) Song, H.; Li, H.-W.; Munson, M. S.; Van Ha, T. G.; Ismagilov, R. F. Anal. Chem. 
2006, 78, 4839-4849. 
(123) Song, P.; Hershey, N. D.; Mabrouk, O. S.; Slaney, T. R.; Kennedy, R. T. Anal. 
Chem. 2012, 84, 4659-4664. 
(124) Wang, X. L.; Zhu, Y.; Fang, Q. Analyst 2014, 139, 191-197. 
(125) Sun, X.; Tang, K.; Smith, R.; Kelly, R. Microfluid. Nanofluid. 2013, 15, 117-126. 
(126) Yan, S. Q.; Sloane, B. F. Biol. Chem. 2003, 384, 845-854. 
(127) Huryn, D. M.; Smith, A. B., III. Curr. Top. Med. Chem. 2009, 9, 1206-1216. 
(128) Palermo, C.; Joyce, J. A. Trends Pharmacol. Sci. 2008, 29, 22-28. 
(129) Otto, H. H.; Schirmeister, T. Chem. Rev. 1997, 97, 133-171. 
(130) Frlan, R.; Gobec, S. Curr. Med. Chem. 2006, 13, 2309-2327. 
(131) Kim, C.; Lee, D.; Kim, C.; Lee, K.; Lee, C.; Ahn, I. Anal. Chem. 2014, 86, 3825-
3833. 
(132) Kaminski, T. S.; Jakiela, S.; Czekalska, M. A.; Postek, W.; Garstecki, P. Lab Chip 
2012, 12, 3995-4002. 
(133) Chabert, M.; Dorfman, K. D.; de Cremoux, P.; Roeraade, J.; Viovy, J. L. Anal. 
Chem. 2006, 78, 7722-7728. 
(134) Collins, P. R.; Stack, C. M.; O'Neill, S. M.; Doyle, S.; Ryan, T.; Brennan, G. P.; 
Mousley, A.; Stewart, M.; Maule, A. G.; Dalton, J. P.; Donnelly, S. J. Biol. Chem. 2004, 
279, 17038-17046. 
 134 
 
(135) Sripa, J.; Brindley, P. J.; Sripa, B.; Loukas, A.; Kaewkes, S.; Laha, T. Parasitol. Int. 
2012, 61, 191-195. 
(136) Scaffa, P. M. C.; Vidal, C. M. P.; Barros, N.; Gesteira, T. F.; Carmona, A. K.; 
Breschi, L.; Pashley, D. H.; Tjaderhane, L.; Tersariol, I. L. S.; Nascimento, F. D.; 
Carrilho, M. R. J. Dent. Res. 2012, 91, 420-425. 
(137) Wen, L.; Tha, S.; Sutton, V.; Steel, K.; Rahman, F.; McConnell, M.; Chmielowski, 
J.; Liang, K.; Obregon, R.; LaFollette, J.; Berryman, L.; Keefer, R.; Bordowitz, M.; Ye, 
A.; Hunter, J.; Huang, J.-K.; McConnell, R. M. In Molecular Cloning - Selected 
Applications in Medicine and Biology, Brown, G., Ed.; InTech, 2011, pp 37-58. 
(138) Kaeppler, U.; Schirmeister, T. Med. Chem. 2005, 1, 361-370. 
(139) Wang, T. Discovery and characterization of novel inhibitors against cathepsin L 
and exploring their potential as anti Ebola/ SARS virus infection therapeutics. University 
of Pennsylvannia, ProQuest, 2012. 
(140) Liu, Y.; Huang, V.; Chao, T.; Hsiao, C.; Lin, A.; Chang, M.; Chow, L. Biochem. 
Biophys. Res. Commun. 2005, 333, 194-199. 
(141) Kim, Y.; Mandadapu, S. R.; Groutas, W. C.; Chang, K. Antivir. Res. 2013, 97, 161-
168. 
(142) Kawada, A.; Hara, K. J.; Kominami, E.; Hiruma, M.; Noguchi, H.; Ishibashi, A. 
Arch. Dermatol. Res. 1997, 289, 87-93. 
(143) Khedr, N. F.; El-Ashmawy, N. E.; El-Bahrawy, H. A.; Haggag, A. A.; El-Abd, E. E. 
Fund. Clin. Pharmacol. 2013, 27, 526-534. 
(144) Bork, S.; Yokoyama, N.; Matsuo, T.; Claveria, F. G.; Fujisaki, K.; Igarashi, I. Am. 
J. Trop. Med. Hyg. 2003, 68, 334-340. 
(145) Tsuji, N.; Miyoshi, T.; Battsetseg, B.; Matsuo, T.; Xuan, X.; Fujisaki, K. PLoS 
Pathog. 2008, 4, e1000062. 
(146) Martins, T. M.; do Rosário, V. E.; Domingos, A. Exp. Parasitol. 2011, 127, 184-
194. 
(147) Baici, A.; Lang, A. FEBS Lett. 1990, 277, 93-96. 
(148) Yaron, M.; Shirazi, I.; Yaron, I. Osteoarthr. Cartilage. 1999, 7, 272-280. 
(149) Forbes, C. D.; Toth, J. G.; Ozbal, C. C.; LaMarr, W. A.; Pendleton, J. A.; Rocks, S.; 
Gedrich, R. W.; Osterman, D. G.; Landro, J. A.; Lumb, K. J. J. Biomol. Screening 2007, 
12, 628-634. 
(150) Highkin, M. K.; Yates, M. P.; Nemirovskiy, O. V.; Lamarr, W. A.; Munie, G. E.; 
Rains, J. W.; Masferrer, J. L.; Nagiec, M. M. J. Biomol. Screening 2011, 16, 272-277. 
(151) Risticevic, S.; Niri, V. H.; Vuckovic, D.; Pawliszyn, J. Anal. Bioanal.Chem. 2009, 
393, 781-795. 
(152) Rule, G.; Henion, J. J. Am. Soc. Mass. Spectrom. 1999, 10, 1322-1327. 
 135 
 
(153) Rule, G.; Chapple, M.; Henion, J. Anal. Chem. 2000, 73, 439-443. 
(154) Morris, B. J. Free Radical Biol. Med. 2013, 56, 133-171. 
(155) Finkel, T.; Deng, C.-X.; Mostoslavsky, R. Nature 2009, 460, 587-591. 
(156) Lavu, S.; Boss, O.; Elliott, P. J.; Lambert, P. D. Nat Rev Drug Discov 2008, 7, 841-
853. 
(157) Zhou, Y.; Mabrouk, O.; Kennedy, R. J. Am. Soc. Mass. Spectrom. 2013, 24, 1700-
1709. 
(158) Trapp, J.; Meier, R.; Hongwiset, D.; Kassack, M. U.; Sippl, W.; Jung, M. 
ChemMedChem 2007, 2, 1419-1431. 
(159) Napper, A. D.; Hixon, J.; McDonagh, T.; Keavey, K.; Pons, J.-F.; Barker, J.; Yau, 
W. T.; Amouzegh, P.; Flegg, A.; Hamelin, E.; Thomas, R. J.; Kates, M.; Jones, S.; Navia, 
M. A.; Saunders, J. O.; DiStefano, P. S.; Curtis, R. J. Med. Chem. 2005, 48, 8045-8054. 
(160) Peck, B.; Chen, C.-Y.; Ho, K.-K.; Di Fruscia, P.; Myatt, S. S.; Coombes, R. C.; 
Fuchter, M. J.; Hsiao, C.; Lam, E. W. Mol. Cancer Ther. 2010, 9, 844-855. 
(161) Sacconnay, L.; Angleviel, M.; Randazzo, G. M.; Marçal Ferreira Queiroz, M.; 
Ferreira Queiroz, E.; Wolfender, J. L.; Carrupt, P. A.; Nurisso, A. PLoS Negl. Trop. Dis. 
2014, 8, e2689. 
(162) Ryckewaert, L.; Sacconnay, L.; Carrupt, P.; Nurisso, A.; SimõesPires, C. Toxicol. 
Lett. 2014, 229, 374-380. 
(163) Bitterman, K. J.; Anderson, R. M.; Cohen, H. Y.; Latorre-Esteves, M.; Sinclair, D. 
A. J. Biol. Chem. 2002, 277, 45099-45107. 
(164) Mai, A.; Massa, S.; Lavu, S.; Pezzi, R.; Simeoni, S.; Ragno, R.; Mariotti, F. R.; 
Chiani, F.; Camilloni, G.; Sinclair, D. A. J. Med. Chem. 2005, 48, 7789-7795. 
(165) Lain, S.; Hollick, J. J.; Campbell, J.; Staples, O. D.; Higgins, M.; Aoubala, M.; 
McCarthy, A.; Appleyard, V.; Murray, K. E.; Baker, L.; Thompson, A.; Mathers, J.; 
Holland, S. J.; Stark, M. J. R.; Pass, G.; Woods, J.; Lane, D. P.; Westwood, N. J. Cancer 
Cell, 13, 454-463. 
(166) Parenti, M. D.; Grozio, A.; Bauer, I.; Galeno, L.; Damonte, P.; Millo, E.; Sociali, 
G.; Franceschi, C.; Ballestrero, A.; Bruzzone, S.; Del Rio, A.; Nencioni, A. J. Med. Chem. 
2014, 57, 4796-4804. 
(167) Michishita, E.; McCord, R. A.; Boxer, L. D.; Barber, M. F.; Hong, T.; Gozani, O.; 
Chua, K. F. Cell Cycle 2009, 8, 2664-2666. 
(168) Bladergroen, M. R.; Derks, R. J. E.; Nicolardi, S.; de Visser, B.; van Berloo, S.; 
van der Burgt, Y. E. M.; Deelder, A. M. J. Proteomics 2012, 77, 144-153. 
(169) Li, Q. Novel approaches to high sensitivity capillary liquid chromatography-mass 
spectrometry and application to in vivo neuropeptide monitoring. Dissertation, 
University of Michigan, 2010. 
 136 
 
(170) Brideau, C.; Gunter, B.; Pikounis, B.; Liaw, A. J. Biomol. Screening 2003, 8, 634-
647. 
(171) Zhang, X. D. J. Biomol. Screening 2011, 16, 775-785. 
 
 
